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ABSTRACT 
Background 
Pulmonary tuberculosis (PTB) is curable but is still a major health problem. PTB is associated to 
chronic lung impairment even after microbiological cure. The type, severity and risk factor for 
lung impairment (LI) are poorly described. The prevalence of LI and reference equations have not 
been established in Mozambican healthy population. 
Methods 
A cohort of PTB patients was followed for 52 weeks after TB diagnosis (2014 to 2016), spirometry 
and 6-Minute Walk Test was assessed at weeks 8, 26 and 52 of follow-up, in Mavalane, Maputo. 
Saint George Respiratory Questionnaire (SGRQ) was evaluated during treatment. In 2017, the 
prevalence of lung impairment and 6-Minute Walk Test were evaluated in healthy volunteers from 
the same neighbourhood. 
Results 
The proportion of LI is 73,3% on week 8, declining to 67,7% at week 26 and 61,3% (26% of 
moderate-severe) at week 52 in PTB patients. On week 52 the mean Vital Capacity (FVC) is 2.65l 
(66.7% of predicted) in participants with LI versus 3.68l (90% of predicted) in participants without 
LI. All study participants suffered from pulmonary restriction (except one). Female sex (RRR = 
5), higher CD4 in HIV positives (RRR: 7.33) were significantly associated with LI. The increase 
of haemoglobin was protective (RRR = 0.61). The PTB patients travelled a mean distance of 442 
meters on week 52 and a mean total score of 5.58 in SGRQ. 
The proportion of LI in the Healthy volunteers was 20%, with 19,35% of restriction (one case of 
obstruction) mean FVC of 3.27l (89.4% of predicted) and FEV1 of 2.7l (93.80% of predicted). 
Conclusion 
Pulmonary restriction occurs in a fifth of healthy volunteer, it develops early during TB disease or 
treatment affecting more than half of the PTB patients. There is a need of more studies on lung 
outcome in PTB and to establish reference equation in healthy volunteers. 
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1. INTRODUCTION 
 
Tuberculosis (TB) and its resistant forms continues being important causes of morbidity and mor-
tality worldwide although curable, with around 10 million prevalent cases each year and around 
1.3 million death in 2017 [1]. In low middle income countries (LMIC) the TB epidemic is driven 
by HIV, undernutrition, diabetes, smoking and alcohol consumption [1]. Between 1995 and 2015, 
an estimated 66 million lives were saved through the implementation of Directly Observed Treat-
ment, Short-course (DOTS) by the National TB Programs in many countries worldwide. Early TB 
diagnosis and initiation of anti-microbial treatment are key elements of the DOTS strategy [1]. 
Many of those treated TB patients, however, undergo pulmonary anatomical changes secondary 
to illness, such as parenchyma structural damage including bronchovascular distortion, bronchiec-
tasis, emphysematous and fibrotic band formations, which are leading to a reduction in overall 
lung compliance. These anatomical changes result in radiographic and functional changes that may 
remain after microbiological cure [2-5]. Finally, chronic lung damage can lead to oxygenation 
problems and consecutive pulmonary hypertension which further results in cardiac damage and 
heart failure. 
The current end TB strategy focus on reduction of TB associated mortality, TB incidence and also 
social and economic burden to individual and households. Patients are not followed after cure, this 
results in weak evidence on chronic lung disease post TB. Further, the type and severity grades of 
post TB lung disease as well as associated risk factors are not well described. Consequently, there 
are no treatment suggestion or guidelines for patients with chronic pulmonary symptoms and func-
tion impairments existent. Although the number of studies on post TB lung disease have been 
increasing since 2010, only three TB treatment guidelines acknowledge post TB lung disease [6]. 
In LMIC the capacity (Spirometry) and management of chronic lung conditions is deficient as 
programs are not designed for long time follow up of TB patients and focus only on the microbi-
ology cure. 
Weak evidence exists about the main diseases and conditions after TB treatment. Pulmonary tu-
berculosis (PTB) is one important risk factor for chronic lung disease due to residual lung damage 
[6]. In recent years there is increased evidence that in LMIC [7] COPD is often associated with 
TB, in contrast to high income countries (HIC) where smoking is the main risk factor. Chronic 
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Pulmonary Lung disease (COPD) is globally the third most important cause of death [6]. Based 
on the global burden of disease projections, TB and COPD are among the 10 leading causes of 
death and disability for low- and middle-income countries at the beginning of the 21st century 
(sixth and eight, respectively) [8, 9]. 
In order to address the existing knowledge gap a prospective cohort facility based study was con-
ducted in Maputo Mozambique, a LMIC with the highest TB rates in the world (551 per 100 000 
inhabitants) [1]. In this study PTB patients were followed for one year after their TB diagnosis, 
and pulmonary lung function (spirometry and 6-minute walk test), clinical, socio-economical and 
environment risk factors were longitudinally assessed. 
Additionally, a healthy volunteers group control was established in order to enable comparisons 
of the spirometry (Lung impairment, patterns) and 6-minute walk test results of (previous) TB 
patients with results from the healthy population. 
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2. LITERATURE REVIEW 
I. Global TB Burden 
TB is the ninth cause of death and the leading cause of death due to a single agent worldwide 
ranking above HIV [1]. It is estimated that 1.7 billion people (23% of world population) are in-
fected with TB and at risk of developing active disease during their lifetime, People Living with 
HIV (PLHIV) are at a higher risk with estimated risk of 10% per year, compared to 5-10% life-
time in HIV negative [10]. 
In 2017, 10 million (9-11.1 million) people: 5.8 million man, 3.2 million woman and 1.0 million 
children developed TB and 1.6 million died (300 000 with HIV) [1]. The 30 High burden countries 
(HBC) accounted for 87% of all estimated incident cases worldwide. Two thirds of the cases hap-
pened in 8 countries: India (27%), China (9%), Indonesia (8%), the Philippines (6%), Pakistan 
(5%), Nigeria (4%), Bangladesh (4%) and South Africa (3%). 9% of all TB cases worldwide were 
PLHIV, with 72% of them living in Africa [1]. Sub-Saharan Africa and Southeast Asia presented 
incidence rates above 100 cases per a 100 000 population per year as in Figure 2-1. 
 
Figure 2-1 Estimated TB incidence rates in 2017 
Source: World TB Report 2018 [1] 
 
The rising numbers of drug resistant TB cases constitute a global public health crisis, with 558 000 
(483 000 – 639 000) people diagnosed with Rifampicin resistant TB (RR-TB), 82% had Multi-
Drug Resistant TB (MDR) with additional resistance to Isoniazid (INH) in 2017 [1]. 
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In 2017, 6.7 million (6.4 new or relapse episodes) TB cases were notified to National TB Pro-
grammes (NTPs) worldwide. The coverage of drug resistance testing was 24% for new TB patients 
and 70% for previously treated patients. In addition, 60% of notified cases had a documented HIV 
result. There is a gap of 3.4 million between the number of notification and the best estimated 
number of cases (6.6 million vs 10 million) [1] as result of underdiagnosing and underreporting. 
Most death from TB can be prevented by early diagnosis and initiation of an appropriate treatment 
regimen. In 2017, the global TB treatment coverage was 64% (58-72) with a treatment success 
rate of 82% cases globally. Thus, it is estimated that 66 million TB cases have successfully treated 
from 1995 to 2015 [1]. 
Despite decreasing TB estimated incidence rates globally, TB related morbidity and mortality 
shows slow reductions in countries of Sub Saharan Africa [1] and in some cases case notification 
are increasing due to the efforts to find the missing case including availability resistance testing. 
 
II. TB and HIV burden in Mozambique 
Mozambique has a triple burden of disease with high rates of TB, TB/HIV and MDR TB being 
listed in the three World Health Organization (WHO) lists: 30 high burden countries (HBC) for 
Absolute TB cases burden, HIV/TB co-infection burden and MDR-TB burden (Figure 2-2). 
 
Figure 2-2 List of WHO high burden countries – Mozambique highlighted 
Source: World TB Report 2018 [1] 
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In 2017, 86 515 TB cases were notified in Mozambique. Mozambique (551/100 000 inhabitants) 
together with Democratic People’s Republic of Korea, The Philippines and South Africa are the 
few countries with estimated incidence rates above 500 TB cases per 100 000 Inhabitants. The 
mortality is estimated at 163/100 000 (116-217) inhabitants, implying a case fatality ratio of 0.31 
(0.17-0.46) [1]. 
TB treatment coverage is 52% with a reported treatment success of 90% among new and relapse 
cases registered in 2016 [1]. 
Despite continuous increase in the notification rates from 2004 to 2016 (Figure 2-3), Mozambique 
is notifying less than half of its cases due to gaps and weakness in the health system, underdiag-
nosis, underreporting and inadequate access to health services. WHO estimated 163 000 cases 
versus 86 515 notified by the NTP in 2017 [1]. The missed cases occur in vulnerable groups, 
children and PLHIV resulting into high mortality and continuous transmission the community. 
HIV prevalence rate at ages 15-49 years countrywide was 13.2% (11.9-14.4), 15.4% in females 
and 10.1% in males in 2015. Southern provinces Maputo city, Maputo province and Gaza present 
16.9%, 22.9% and 24.4% respectively [11]. The TB notification of 529/100 000 population in 
Maputo city is close to WHO estimation for Mozambique (551/100 000), all southern provinces 
have higher TB notification (Figure 2-4) that is a reflex of high HIV prevalence and better diag-
nostic coverage. 
 
Figure 2-3 Annual notification rates per 100 000 population compared to WHO estimations 2004-2016 
Source: NTP 2016 report [12] and WHO global TB Report [1] 
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Figure 2-4 TB cases notification rates per 100 000 population per province 
 Source: NTP 2016 report [12] 
 
In Mozambique, HIV infection is still an important cause of morbidity and mortality1 with 130 
000 new infections (110 000 adults aged 15 and over and 18 000 children aged 0-142) and 70 000 
deaths reported in 2017 [13] . According to population-based surveys conducted in Mozambique, 
HIV/AIDS prevalence increased from 11.5% to 13.2% between 2009 and 2015 in adults aged 15-
49 years (not statically significant). Women are the most affected by HIV/AIDS, with an infection 
rate of 15.4% - 20.5% among women in urban areas and 12.6% among women in rural areas. In 
men, the infection rate is 10.1%, with 12.3% in urban areas, and 8.6% in rural areas. HIV infection 
is directly related to age, peaking between the ages of 35-39 years in both sexes, with prevalence 
of 17.5% in men and 23.4% in women [14]. 
The HIV epidemic in Mozambique is widespread with a higher infection rate in the southern region, 
followed by the central and the northern regions of the country. In 2017, an estimated 2.1 million 
people were living with HIV, and 170 000 of these were children aged 0-14 years [13]. The prov-
ince of Gaza, which is located in the southern region, has the highest HIV infection rate at 24.4%, 
followed by Maputo Province, further south, at 22.9%, and Maputo City, at 16.9%. The province 
of Tete, in the central region, has the lowest infection rate at 5.2%, followed by Nampula Province 
at 5.7%, and Niassa Province, at 7.8%. The HIV infection rate is highest in urban areas, at 16.8%, 
compared to rural areas at 11% [14]. 
 
 
1 Means the number of people infected by other diseases and the number of deaths due other disease, comparing to people tested. 
2 www.unaids.org 2017 
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In Mozambique, antiretroviral therapy (ART) was introduced in 2003, with massive scale-up ef-
forts in all regions of the country starting in 2005. Estimations show that in 2017, 1 156 101 indi-
viduals in the national health system were on ART, 1 069 593 were adults and 86 508 were chil-
dren between 0-14 years of age. ART coverage at the national level is 54% in adults and 51% in 
children [13]. In 2017, viral suppression (HIV viral load <1000 copies / ml) in the individuals on 
ART was estimated to be 65%—69% in women and 48% in men [14]. 
 
 
Figure 2-5 Proportion of man e woman 15-49 years old that are HIV positive 
Source: IMASIDA [14] 
 
III. TB Diagnostic and Treatment in Mozambique 
All patients attending to a Health Facility (HF) should be screened for TB irrespective of the reason 
for the consultation. Priority groups for TB screening includes pregnant woman, children between 
0-14 years old, PLHIV, chronic or immunosuppressed patients, individuals with close contact with 
TB patients and risk group population (health care professionals, miners, prisoners and among 
others). In Mozambique HF are implementing the Find cases Actively, Separate temporarily and 
Treat effectively (FAST) strategy and training and placing cough officers to increase the number 
of patients screened for TB. Community health workers are also engaged to increase the number 
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of contact screening at the community level by symptom screening and referral for testing and 
treatment initiation at the HF. 
Any potential delay in TB diagnostic by the patient or the health system may increase the risk for 
severe disease, lung impairment and mortality in TB patients. A study report from Sofala Province 
(central region of the country) indicated that the median total delay for TB diagnostic (patient 
delay and health system delay) was 150 days (IQR 91-240) with a median of 61 days (IQR 28-
113) related to the patient delay and 62 days (IQR 37-120) related to the health system delay [15]. 
Farming, visiting a traditional healer, low knowledge on TB and coexistence of a chronic disease 
were associated to increased patient delay [15]. 
Smear microscopy is still the most used screening test in presumptive TB cases in HF in Mozam-
bique. HF with a GeneXpert device are recommended to perform initial diagnosis by running both 
Xpert MTB/RIF and the smear microscopy. Mozambique has three reference laboratories: the TB 
national reference lab in Maputo (Maputo city - southern region), Beira reference lab (Sofala prov-
ince - Central region) and Nampula reference lab (Nampula province – northern region). For ad-
vanced TB laboratory assays such as line probe assay (LPA), culture and Drug Sensibility Testing 
(DST), the biological samples are referred to these three regional laboratories. There are still some 
challenges with sample referring system that are related to delivery of viable samples and main-
taining the cold chain during the sample shipment-transportation from the HF to the reference 
laboratories. Despite the increased availability of diagnostic tools, the majority of cases are not 
bacteriologically confirmed (clinical or radiological diagnosis). 
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Figure 2-6 Susceptible TB case notified, Cases bacteriologically confirmed and extrapulmonary TB cases 2010-
2016 
Source: NTP 2016 report [12] 
 
Figure 2-7 Susceptible TB case notified, Proportion of cases bacteriologically confirmed and extrapulmonary 
TB cases 2010-2016. 
Source: NTP report 2016 [12] 
The DOTS program was stablished in the early 80s in Mozambique. Currently, all public HFs have 
trained staff to provide TB treatment. 
The susceptible TB (STB) cases are treated with rifampicin based fixed dose combination (FDC) 
during intensive phase Rifampicin-R, Isoniazid-H, Pyrazinamide-Z and Ethambutol-E are given 
for 2 month and during maintenance phase R and H are prescribed for additional 4 months. 
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Table 2-1 FDC drugs available for susceptible TB Treatment in Mozambique 
 
 
 
 
The follow-up of patients with STB include clinical follow-up (weight gain, signs and symptoms 
improvement and adverse event monitoring) a bacteriological follow-up (smear) at months 2 and 
5. The follow-up does not include monitoring of lung function and pulmonary rehabilitation during 
or after the TB treatment completion. TB treatment success for STB is recommend to be equal or 
above 85% by WHO, Mozambique had 95% in 2017 [1]. 
For MDR TB there are two regimens: 20 months regimen and the short-standardized regimen 
(STR) (9-11 months), Patients with resistance to quinolones or injectables, exposure to patients 
with resistance to quinolones or injectables, exposure to second line drugs more than a month, 
pregnancy, intolerance to a short regimen drug, extrapulmonary TB and extensive disease are non-
eligible to the STR and therefore are treated with the 20 months TB regimen. 
The treatment and testing are free of charge. However, there are always indirect costs incurred by 
the patients in seeking and staying in care for TB in Mozambique. 
  
 
 
3 Associated to Ethambutol 100 mg in intensive phase 
Formulation Drugs and dosage                       
(mg) 
Treatment period   
(Months) 
4 FDC RHZE                  
(150, 75, 400, 275) 
Intensive                    
(2 months) 
2 FDC adults RH                      
(150, 75) 
Maintenance               
(4 months) 
3 FDC paediatrics 
(dispersible pills) 
RHZ                          
(75, 50, 150)3 
Intensive                    
(2 months) 
2 FDC paediatrics 
(dispersible pills) 
RH                         
(75, 50) 
Maintenance                 
(4 months) 
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Table 2-2 Standardized MDR-TB treatment regimens in Mozambique 
Standardized 20 months regimen 
Treatment period (route of 
administration) 
Duration Drugs 
Intensive (Injectables and 
oral) 
6-8 months 
(Depends on cul-
ture conversion) 
Capreomycin (Cm), Moxifloxacin 
(Mfx), Cycloserin 
(Cs), Protionamide (Pro), Ethambutol 
(E), Pyrazinamide(Z) 
Maintenance (Oral) 12 months Moxifloxacin (Mfx), Cycloserin (Cs), 
Protionamide 
(Pro), Ethambutol (E), Pyrazinamide 
(Z) 
Standardized short regimen (9-11 months) 
Treatment period (route of 
administration) 
Duration Drugs 
Intensive (Injectables and 
oral) 
4-6 months 
(Depends on cul-
ture conversion) 
Capreomycin (Cm), Moxifloxacin* 
(Mfx) 
Protionamide (Pto), Clofazimine (Cfz), 
Pyrazinamide 
(Z), Isoniazida**(Hh), Ethambutol (E) 
Maintenance (Oral) 5 months Moxifloxacin (Mfx), Clofazimine (Cfz), 
Pyrazinamide (Z), Ethambutol (E) 
 
In case of resistance to other TB drugs an individualized treatment is assigned by a national ther-
apeutic TB Committee of Ministry of Health (MoH). 
Follow-up of patients with MDR-TB treatment includes bacteriology confirmation. Laboratory 
follow up includes LPA, cultures and DST, and safety tests (hemogram, creatinine, sodium, ala-
nine aminotransferase-ALT, aspartate aminotransferase-AST, thyroid-stimulating hormone-TSH, 
glycemia, pregnancy). The clinical follow-up includes weight gain, signs and symptoms improve-
ment, adverse event monitoring that includes electrocardiogram (ECG) and audiometry as appli-
cable and chest x-ray. The follow-up does not include lung function or pulmonary rehabilitation 
during or after TB Treatment period. 
In Mozambique, less than half of the TB patients who started MDR treatment in 2015 achieved 
treatment success (treatment success rate of 48%) [1]. Both STB and MDR-TB are only followed 
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under the routine TB clinics in HF until treatment completion or cure. The specialized services for 
the management of complicated cases and lung sequel are scarce in the country. 
 
IV. Post TB lung disease burden 
Treatment success in TB is defined as cured (smear or culture conversion) or treatment completed. 
These are the main objective of the WHO End TB strategy and national TB programs for TB 
control. After successful treatment completion there is no further follow-up of patients recom-
mended [16]. However more than half of TB patients remain with symptoms or lung impairment 
after successful TB treatment completion [17-19]. 
Post TB lung disease (PTLD) is not a well-defined entity. Several conditions are classified here: 
radiological abnormalities, respiratory symptoms, pulmonary function impairment (includes air-
flow obstruction, restriction and the combination), post-TB aspergillosis, bronchiectasis, haemop-
tysis, bronchial stenosis, obstructive disease and TB sequelae [6]. 
In the pre-antibiotic era high rates of obstructive airways disease were observed in patient exiting 
the sanatorium [20]. In one study it could be shown that PTB patients usually develops maximum 
loss of lung function within six months of the diagnosis of tuberculosis and it stabilizes 18 months 
after completion of TB treatment [21]. 
A study in Tanzania showed abnormal lung function in 74% of PTB patients at week 20 of treat-
ment (42% of obstructive, 19% of mixed and 13% of restrictive). The predictor for abnormal lung 
function were recurrent TB (adjusted odds ratio 2.8 CI: 1.247-6.0106), HIV negative status (1.7, 
1.055-2.583), age more than 40 years (1.7, 1.080-2.804) and male sex (1.7, 1,123-2.614) [7]. 
In another study from Tanzania has shown that recurrent TB was the most important risk factor 
associated to a decrease in Forced Expiratory Flow (FEF) 25-75 as well as % of predicted FEV1 
[22]. 
In South Africa a study with 33 MDR patients successfully treated for MDR TB in Limpopo, only 
2 (6%) had normal pulmonary function tests (PFT), 14 (42%) had restrictive disease, 13 (39%) 
mixed disease and 4 (12%) had obstructive disease with a median FVC of 61% of predicted and 
FEV1 of 56% of predicted [23]. 
Black South African working in golden mines (n = 27 660) with 1 episode of TB in 2 137, 2 
episodes of TB in 366, 3 episodes of TB in 93 and 4 or more episodes of TB in 17, presented 
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chronic airflow impairment (FEV <80% of predicted) 18.4%, 27.1% and 35.2% respectively and 
an average decrease of FEV1 of about 180 ml, 362 ml, 462 ml and 964 ml respectively [21]. 
Another study conducted in South East Asia, 200 PTB Indonesian patients had shown that at least 
27% residual moderate to severe pulmonary function impairment (FEV % < 60) at month six of 
TB treatment and 57% of the patients yet had respiratory symptoms despite achieving successful 
treatment and all reported a good quality of life [17]. The travelled distance on 6MWT was 479 
meters (IQR 460- 529) in controls vs 470 meters (IQR 418-515) after month 6 (p= 0.02) and Saint 
George Respiratory Questionnaire (SGRQ), was zero (IQR 0-2.9) in controls vs 4.9 (1.7-8.8) in 
TB patients at month 6 [17]. 
An observational case control study, conducted in India 50-65 years old patients with TB Sequelae 
(30 males/ 30 females) were compared to healthy control matched by gender. All healthy volun-
teers had a VO2max > 21 ml/kg/minute while in the TB Sequelae group only 60% of man and 36% 
of woman had the VO2max > 21ml/kg/minute during the 6MWT [3]. 
As part of the South Korean COPD prevalence survey, the prevalence of airflow obstruction (AFO) 
was compared between participants with and without radiologic signs of TB. In this study, 1.384 
subject were included in this analysis with a median age of 51 years old. 167 (12,1%) had radio-
logic changes related to TB, among these 44 (26,3%) showed AFO and only 8,6% of participant 
without radiologic changes showed AFO. The Adjusted OR for this difference was 3.12 (95% CI 
2,01, 4.67) [24]. 
In Texas, United States of America (USA) a case control study compared pulmonary TB patient 
(cases) to latent TB infected patients (comparison subjects). In this study, 59% of cases had lung 
impairment at week 20 (restrictive 31%, obstructive 15% and mixed 13%) while for the controls 
only 20% had lung impairment (restrictive 16%, obstructive 3% and mixed 1%). Severe pulmo-
nary dysfunction was more between the cases 10% with FVC lower than 50% vs controls 0,48%. 
TB patients were 5 times more likely to have lung impairment (OR, 5.37; 95% CI, 2.98 to 9.68) 
[18]. 
During the same period, another cohort (n=123) showed different results. In this study, 9% had 
severe impairment (< 50% predicted FVC), 22% of subject had a restrictive pattern, 16% an ob-
structive pattern and mixed pattern was observed in 14%. This study did not show any evidence 
that the delay in diagnostic and treatment is associated with pulmonary impairment and suggested 
that impairment when present may be permanent [2]. 
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Another study in the same setting estimated that 177 TB patients lost a total of 1189 disability 
adjusted life years (DALYS), with 247 DALYS lost from years of life lost (16 deaths), and 915 
DALYS lost from acute (from TB diagnosis to treatment) and chronic (after TB treatment) disa-
bility. Years lived with disability constituted the majority of TB burden (75%) and 73% being 
years lived with chronic disability [25]. 
The population based (n=5 571), multicenter, cross sectional study Platino (Proyeto Latinoameri-
cano de Investigaticion en Obstrucion Pulmonar) performed in Latin America using a post-bron-
chodilator spirometry enrolled 5 571 subjects with age above 40 years old. Individuals from five 
Latin America countries showed a prevalence of AFO of 30.7% among those with history of TB 
and 13.9% among those without history [9]. 
In Minas Gerais, Brazil pulmonary function test in 50 patients with TB Sequelae found 34% of 
Mixed ventilatory disorder, 12% of obstructive and 9% of restrictive [26]. 
A cases series of MDR TB patients in Rio de Janeiro, Brazil showed among 18 patients found 
obstructive pattern in 39%, restrictive pattern in 22% and mixed pattern in 17% of patients. The 
patient also reported a mild reduced functional capacity (evaluated by 6MWT) and quality of life 
(assessed by Airways Respiratory Questionnaire 20) [27]. 
In Lima, Perú, patients with cured DS-TB and MDR-TB patients and unexposed participants (com-
parison group) were evaluated to assess the lung impairment. There was minimal lung impairment 
among patients treated for DS-TB when compared with the control group. However, the MDR 
cured patient had lower lung volumes with an adjust mean differences -370 ml (95% CI – 611, -
97), and with an adjusted OR 4.89 (95% CI 1.27- 18.78) [28]. 
In a worldwide study (19 sites from Africa, Asia, Europe and North America) performed in adults 
40 years old or above, multicenter, cross sectional, general population-based Burden of Obstruc-
tive Lung Disease (BOLD), self-reported history of TB was associated with airflow obstruction 
adjusted odds ratio 2.51 (95% CI 1.83-3.42) and spirometry restriction 2.13 (95% CI 1.43 – 3.19). 
The airflow obstruction association was more preeminent in LMIC, Cape Town (n=846) the OR 
was 3.49 (2.19-5.57) and for restriction 1.47 (0.95-2.27) [29]. 
Successfully treated TB patient also present a higher mortality when compared with the general 
population [30, 31]. Miller et al. found an excess of 7.6 deaths per 1000 person years (8.8 vs 1.2; 
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p<.001) when comparing all-cause mortality between posttreatment TB patients vs a latent TB 
comparison group in USA. 
There is a knowledge gap in this area, from a total of 212 only three international guidelines re-
ferred to TB sequelae but did not address diagnosis and management of the case. Since 2010 the 
number of studies in this area have been increase although Post TB chronic lung disease [6]. 
 
Figure 2-8 Periodical distribution of research articles on post-tuberculosis (TB) chronic lung disorders. 
*Aspergillosis, bronchiectasis, haemoptysis, bronchial stenosis, pulmonary hypertension, emphysema, fibrosis, 
asthma. 
Source: Van Kampen et al. [6]. 
 
Chronic obstructive pulmonary disease (COPD) is closely linked to TB in LMIC and affects 65 
million people worldwide and is responsible for 3 million deaths annually (291 per 100 000) [19, 
28] was the 3rd cause (Figure 2-7) of death in 2016 [1]. 
COPD includes several conditions causing chronic lung disease culminating in AFO. COPD is on 
the raise globally and remains a neglected global epidemic. COPD is actually the third most com-
mon specific cause of death with 5% of the death. Despite the high prevalence in HIC, 90% of the 
death occurs in the LMIC [19, 28]. The main risk factors for COPD are: Tobacco smoking, Indoor 
air pollution (such as biomass fuel used for cooking and heating), Outdoor air pollution and Oc-
cupational dusts and chemicals (vapors, irritants, and fumes), but many studies [9, 24, 29] have 
shown that TB is a risk factor for COPD in LMIC instead.  
COPD is an important comorbidity in TB Patients, coming in 2nd only to diabetes mellitus[32], 
both diseases evolve with destruction of the Extracellular matrix (ECM) of the lung parenchyma 
and imbalance of the matrix metalloproteinases (MMPs). 
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Figure 2-9 Top cause of death worldwide & estimate number of deaths for HIV and TB 
Source: World TB Report [1] 
 
PTLD diagnosis is not standardized, the assessment in different studies included lung function test 
and exercise capacity (Spirometry and 6MWT), quality of life (SGRQ or Airways respiratory 
questionnaire 20), sign and symptoms. 
 
V. The mechanism and risk factor for Post TB Lung Disease 
The healing process the lung undergoes during and after treatment, can cause excessive fibroses 
and stiffening of the lung parenchyma associated to the incapacity of inhaling completely leading 
restrictive spirometry, in contrast in case airflow obstruction there is incapacity of completely ex-
haling associated with air ways narrowing from excessive inflammation (figure 2-8) [33]. 
In the case of obstructive pattern, the main mechanisms are  
• Cavitation: distorts and obliterates airways. 
• Bronchiectasis and bronchiolises: Destruction of muscular and elastic components of the 
bronchial wall, predisposing patients to recurrent episodes of purulent sputum production, 
haemoptysis and pneumonia. 
In contrast restriction is related to: 
• Abnormal remodelation (fibroses and pleural thickening) the lung. The MMP are respon-
sible for the lung remodelation, inflammation leads to the destruction of extracellular ma-
trix. The MPPs have different roles during mycobacterial infection. MMP 9 contains the 
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infection leading the formation of a granuloma while MMP1 produced by type II pneumo-
cyte is related to alveolar destruction and cavitation [34]. 
There is immense heterogeneity in the type of lesion and ventilatory defect in TB patients. This 
might be related to the host, pathogen and the diverse immunological event following. 
’ 
Figure 2-10 Mechanism and radiographic features associated with Airflow Obstruction and restrictive venti-
latory defect in patients with a history of TB. 
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity. 
Source: Ravimohan et al. [33] 
 
As shown above in the summary of existing literature, several predictors and risk factors for PTLD 
have been poorly and inconsistently described like demographics (age, sex and Body Mass Index 
- BMI), socioeconomic status (education, occupation and monthly income), radiological features 
(extension of lesion and cavitary disease), clinical history (previous episodes of TB, delay to treat-
ment start, childhood respiratory tract infection and clinical improvement after treatment start), 
microbiological (smear quantitative result, Culture time to positivity), behavioural (smoking, 
drinking), environmental (air pollution, indoor air pollution and biomass fuel exposure) and 
comorbidities (diabetes and HIV infection) [35, 36]. 
In India, smoking, education, duration of disease prior to diagnosis and number of previous TB 
treatment we found as significant risk factors for pulmonary impairment [36]. 
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In LMIC although smoking is less prevalent when compared to industrialized countries, patients 
are exposed to multiple lung insulting factor like occupational exposure or indoor air pollution 
(dust, fumes and gases), childhood lower respiratory tract illness and air pollution.  
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3. RATIONALE AND OBJECTIVES 
I. Output 1 
The active lung infection (TB disease) with Mycobacterium tuberculosis (MTB), progresses with 
parenchymal structure damage, which includes bronchovascular distortion, fibrosis, bronchiectasis 
and pleural thickening in many patients [33]. These anatomical changes may result in chronic 
pulmonary symptoms and a long-term reduction of overall lung compliance, including ventilatory 
defects, in up to 70% of successfully treated TB cases [7, 18, 33, 37, 38]. The common clinical 
signs and symptoms shared by most former patients with post TB sequelae are chronic cough with 
and without phlegm, wheezing, breathlessness as well as physical activity limitations [17, 39-41]. 
The clinical assessment usually leads to abnormalities in spirometry, associated to a significant 
morbidity and mortality burden in a high proportion of post-TB patients [6, 30]. Even in developed 
countries such as the USA, previous TB diagnosis was a risk factor for loss in longevity [31, 42]. 
Several studies, including some from the African continent, provided data suggesting that tuber-
culosis and chronic airflow obstruction (COPD) may be interrelated [19, 22, 43, 44]. Both condi-
tions, TB and COPD, are ranked among the ten leading causes of death and disability for low- and 
middle-income countries [9]. 
Ravimohan et al., described several, probably genetically defined, immunological and inflamma-
tory pathways, which may result in the destruction of lung tissue and consecutive function impair-
ment [33]. However, clinical, behavioural or microbiological risk factors for the development of 
pulmonary sequelae were, so far, not systematically assessed. Additionally, demographic, clinical 
(time to diagnosis and comorbidities), occupational (silica dust) and environmental (smoking and 
biomass smoke) factors are described as risk factors for lung impairment [2]. 
The cardiopulmonary morbidity of people with pulmonary TB and the relevant risk factors can be 
evaluated using measures such as pulmonary/physiological function test, quality of life question-
naires as well as by clinical assessment of treatment response and complications [7]. Risk factors 
can be assessed using questionnaires, clinical investigations as well as blood tests. 
In order to assess and quantify TB related cardiopulmonary morbidity and to investigate risk fac-
tors for poor cardiopulmonary TB outcome, several physiological tests (ECG, 6MWT, spirometry) 
might be combined. This are easy to implement but usually not broadly available in most devel-
oping countries. 
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The primary study objective is: 
• To describe the evolution of long-term pulmonary function impairment in Mozambican 
pulmonary TB patients by assessing lung function with spirometry and 6 MWT at different 
time points after TB diagnosis and treatment initiation. 
The secondary objectives are: 
• Determine the type and severity of pulmonary function abnormalities; 
• Describe the association between loss of lung function with radiology images at the begin-
ning of TB treatment; 
• Describe the influence of different risk factors: demographic (sex, age), clinical and labor-
atorial (BMI, HIV infection, haemoglobin, C reactive protein and time to culture conver-
sion), Behavioural (Smoking and drinking habits), environmental (indoor air pollution); 
• Describe Microbiological treatment outcome in patients with and without pulmonary im-
pairment; 
• Describe the functional capacity of TB patients in the 6-MWT including the distance 
walked, fatigue and dyspnoea scores.   
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II. Output 2 
The evaluation of a spirometry test results or a 6MWT is based on the comparison of the actual 
result of a subject to the predicted results based on normal ranges established by equations from 
“normal” populations similar characteristic to the patient (anthropometric where relevant ethnic). 
In our literature search, we did not find information about spirometry and 6MWT reference values 
for the Mozambican population or prediction equations directly applicable to this population. 
Some neighbourhood countries like South Africa and Tanzania have established prediction equa-
tions for their populations. However due to the small sample size of these studies (ideally more 
than 300 subjects should be recruited into such studies [45]) and due to the diversity of African 
populations we know there are some limitations for applying these values (e.g., from South African 
or Tanzania) directly to a Mozambican population. 
Therefore, this study will describe the lung volumes measured by spirometry and the walking dis-
tance measured by 6MWT in Mozambican population. The values obtained from healthy volun-
teers will enable us to quantify the amount of lung impairment and functional capacity lost due to 
TB disease comparing the parameters from healthy volunteers to TB patients (see output 1) living 
in a similar environment and exposed to the same environmental hazards. 
The primary objective of the output II is: 
• To describe the normal lung function capacity (measured by spirometry) and functional 
capacity (measured by 6MWT) in healthy volunteers living in Mavalane area, Maputo, 
Mozambique. 
The secondary objectives are: 
• To compare the lung function values of healthy subjects with the lung outcome of the TB 
cohort (output 1). 
• To determine the Saint George Respiratory Questionnaire (SGRQ) scores in healthy vol-
unteers. 
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4. METHODS AND MATERIALS 
I. Study Setting 
The Mavalane health area is located in a periurban area of Maputo city, with a total population of 
about 891 314 inhabitants in 2017 [46]. Mavalane is greatly overcrowded (Maputo city popula-
tional density is 3670.6 inhabitant per Km2) [46]. Poor sanitation, poor waste disposal, indoor air 
pollution and poor health education in Mavalane are promoting TB infection and the development 
of TB. About 65% of the Mozambican population lives under the poverty line with less than 
USD1.90 per day and with a national average of 43% of stunting in children under 5 years old [47]. 
Maputo city had a HIV prevalence of 16,9% in 2015 [11] which further increases the TB mortality 
and morbidity. HIV is the most important risk factor for the development of active TB in sub-
Saharan Africa. In Maputo city 6 760 all forms of TB were notified in 2016 corresponding to 
529/100 000 [12]. 
The TB Research Unit of Instituto Nacional de Saúde (INS) is located at the premises of the Ma-
valane Health Center. The National TB Program (NTP) diagnosis and treatment clinic is also col-
located in the same place. The Mavalane Health Center offers outpatient and first contact personal 
care health services including MDR TB treatment. On average, the HF reports around 15-20 smear 
positive TB patients and the same amount of smear negative and extrapulmonary TB patients that 
are diagnosed and treated for TB in each month at Mavalane health center. A four modules Xpert 
MTB/ RIF device was established at the study clinic. HIV counselling and HIV rapid tests, hepa-
titis B rapid tests (HBsAg), urine dip stick and LAM analyses were also be performed in the TB 
study clinic. Blood samples were sent for analyses to the nearby study laboratory at Polana Caniço 
Research and Training Center (CISPOC), a research center of INS. All sputum culture related 
methods were performed at the National TB Reference Laboratory of INS. 
TB Treatment was provided and supervised by the National TB program clinic located in the HF. 
Each study participant treated for TB was registered at the Mavalane Health Center. 
 
II. Output I: Lung impairment in TB patients 
a. Study design 
From 14th of June 2014 to 28th of May 2015, TB presumptive or TB confirmed patients referred 
from peripheral health centers (PHC) to Mavalane Health Center for TB diagnosis or treatment 
were approached for participation in this study. All consenting patients were screened for active 
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TB. Additionally, TB presumptive patient identified at Mavalane HC were asked to participate in 
the study. TB diagnosis was established or confirmed by Xpert MTB/RIF assay. 
Patient with a confirmed pulmonary TB were consecutively enrolled in study cohort and prospec-
tively followed for 52 weeks after diagnosis. TB treatment to all study participants was adminis-
tered by the Mavalane NTP treatment clinic and according to the National TB program guidelines. 
All patients, who tested positive for HIV were referred for comprehensive HIV care, treatment and 
further care according to national guidelines. 
The study was embedded in a joint project of CISPOC, Maputo, Mozambique and the Division of 
Infectious Diseases and Tropical Medicine at Ludwig-Maximilian University (LMU), Munich, 
Germany. This collaboration aimed at setting up and further develop a clinical TB Research unit 
in Mozambique. This study also aimed to establish clinical, laboratory capacity, enrol and follow-
up pulmonary TB patients following principle of Good Clinical Practices (GCP) regulated for TB 
treatment trials. The study was registered under ClinicalTrials.gov: NCT02156882. 
In this context, the TB cohort study was used as a pilot to further build capacity of the local staff 
and collect basic information on the clinical, microbiological and TB outcomes characteristics of 
Mozambican TB patients in Maputo city. Therefore, no sample size calculation was performed 
prior to study start. 
b. Eligibility criteria 
i. Inclusion criteria: 
• >/= 18 years old of age. 
• Able and willing to give informed consent to study participation, including HIV-testing 
• Positive TB result by Xpert MTB/RIF performed at the study clinic 
 
ii. Exclusion criteria: 
• TB treatment in the last 6 months 
• Abandoned TB treatment at any time point in the past 
• Suffering from a condition likely to lead to uncooperative behaviour e.g. psychiatric illness 
or alcoholism. 
• Karnofsky score below 50% [48] 
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c. Clinical study procedures 
i. screening visits (visit 1) 
Study related procedures were performed only after the patient has provided informed consent. 
First, a clinical examination and vital signs were performed by the study doctor or delegated med-
ical staff in all patients, followed by capturing of basic demographic data. 
From each participant (including those who were already referred to the study clinic with a positive 
TB screening result) one spot sputum sample was collected either for confirmation of a previously 
positive TB test or for TB screening with Xpert MTB/RIF assay. The analysis of one sputum 
sample in all participants ensured that the baseline qualitative and quantitative readouts were es-
tablished by one consistent standard. In patients with a negative TB result for Xpert MTB/RIF 
assay, screening was repeated using a morning sputum sample, analysed in the study clinic on next 
day (see Figure 4-1) 
All study participants were referred to the National TB Programme for further treatment and/or 
evaluation. Those patients with confirmed TB diagnosis (positive Xpert MTB/RIF test) at screen-
ing (visit 1), got another study appointment for enrolment into the study and baseline (visit 2) and 
further follow up. In all participants with a negative TB testing result, the study ended after patient 
referral to the NTP at the end of screening visit(s) [visit 1]. 
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Figure 4-1 Study work flow and screening algorithm (diagram) 
Source: Adapted from the MaTuTU protocol 
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ii. Baseline (visit 2) 
Those patients with confirmed TB diagnosis (positive Xpert MTB/RIF assay) at screening (visit 
1) were eligible for enrolment into the study. For the baseline visit (visit 2), all patients were asked 
to bring the first sputum they produced in the morning (morning sputum) and to provide a 2nd 
sample (spot sputum) at the study clinic. 
A study questionnaire which comprises questions on patients´ socioeconomic data, clinical symp-
toms, co-morbidities and patients’ history was completed for all study participants. Each patient 
had a chest x-ray if medically justified and if there was no chest x-ray of this patient available 
which was not older than 7 days. 
In addition, one blood sample for HIV-testing including CD4 count (where applicable), full blood 
picture, serum biochemistry and rapid hepatitis B testing were collected. Those patients who were 
diagnosed with HIV were referred to the HIV-clinic for further treatment and care. All HBsAg-
positive patients identified received counselling on measures to prevent or reduce the risk of hep-
atitis B virus- transmission to their household contacts and sexual partners. All patients were ad-
vised how to avoid potential liver damage (e.g. by alcohol). In addition, HBs-Ag-positive patients 
were referred to a specialized service of gastroenterology at Maputo Central Hospital for further 
care and treatment based on the standard of care available at the site. HIV/HBV co-infected indi-
viduals were referred for co-infection treatment with TDF based ART which is part of WHO rec-
ommendations. Finally, TB treatment will be started on the day of the baseline visit (visit 2). 
iii. Follow up visits (Visit 3 to 9) 
Follow up visits were performed according to the schedule of events. On each follow up visit, a 
medical questionnaire recorded for all patients as well as a physical examination by the study 
doctor or a medical officer. Further, clinical treatment data including side effects and TB symp-
toms were collected. All participants were asked to bring an early morning sputum sample to each 
follow up visits as well as to produce a spot sputum sample the study site. In case, a patient should 
not bring a morning sputum sample to the clinic, a second spot sample was collected at the clinic.  
At visits at week 8, 26, a comprehensive pulmonary function assessment was performed in all 
study patients to establish the physiological capacity of the lung of TB patients at those time points. 
This assessment includes ECG, spirometry and 6-minutes walking test (6MWT). 
 
27 
 
iv. visit week 52 (visit 10) 
At this study visit, a medical questionnaire with focus on TB symptoms, TB treatment, relapse and 
treatment failure and a short socioeconomic questionnaire was applied to the patients. If a study 
participant was found to suffer from respiratory symptoms a sputum sample was collected to ex-
clude TB relapse. Symptomatic patients were be referred to the health system for evaluation and 
follow up. Additionally, at this visit the last cardiopulmonary assessment was performed including 
the reversibility test in patient with an obstructive abnormality on spirometry. 
 
d. Laboratory study procedures performed in the study clinic/at the 
Mavalane health center 
For screening procedures, a fresh sputum sample about 0.7ml was used for Xpert MTB/RIF testing 
performed by study staff at the TB research clinic. The rest of the sputum sample was kept at 8°C 
and sent to the TB Reference Laboratory later. HIV rapid testing, was performed in the TB Re-
search Unit following the national testing algorithm and after counselling of the study participants. 
e. Laboratory procedures performed at National TB Reference Labor-
atory 
All TB testing related procedures were performed in the National TB Reference Laboratory of the 
INS under the supervision of one of the study PIs and according to GLP. For each procedure an 
SOP will be in place and the respective staff received an appropriate training on procedures. 
i. Sputum smear microscopy in study laboratory 
Decontaminated and concentrated sputum samples was used for smear microscopy. After Ziehl-
Neelsen staining, the slides were examined with the 100x objective using oil-immersion. Repre-
sentative areas of the slides are read until either 300 fields are read or mycobacteria were found. 
The smear were scored using the WHO/IUATLD [49]. 
ii.  Culture on solid Lowenstein Jensen medium 
Decontaminated and concentrated sputum samples were used for culturing of mycobacteria. LJ 
media were examined weekly for a total of 56 days. The week of first culture growth was reported. 
Colonies suspicious for mycobacteria are examined by Ziehl-Neelsen staining. 
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iii. MGIT liquid culture  
Decontaminated and concentrated sputum samples were used for TB culture. Positive MGIT-cul-
ture was confirmed by Ziehl-Neelsen staining. For M.tb positive cultures the duration of incubation 
until positive result was recorded. 
iv. Speciation of mycobacteria by GenoType® Mycobacterium 
MTB/CM 
Identification of the mycobacteria species were performed from positive solid and/or liquid cul-
tures. The GenoType® Mycobacterium CM is a DNA-STRIP® technology that gives the possi-
bility to diagnose patients with a positive culture result (from solid or liquid culture) for mycobac-
terial growth. If the patient was therefore suspected to suffer from a tuberculosis or mycobacteri-
osis the identification of the particular species helped to decide on an appropriate treatment. 
The GenoType® Mycobacterium CM permits the simultaneous molecular genetic identification 
of the M. tuberculosis complex and 24 of the most common NTM species. 
v. Drug resistance testing using BACTEC® 960 / MGIT liquid cul-
ture 
Tuberculosis phenotypic resistance testing was performed for first line drugs (Isoniazid, Rifam-
picin, Pyrazinamide, Ethambutol and Streptomycin) using Bactec liquid culture system. All pro-
cedures were performed following published standards and/or the instructions of the manufacturer. 
 
f. Safety laboratory procedures 
i. HIV-Testing 
All patients were screened for HIV according to the National Guidelines in Mozambique. In addi-
tion, CD4 cell count was performed in all HIV positive patients. Those patients who were diag-
nosed with HIV were referred to the HIV-clinic for further treatment and care. For CD4 count, 
analyses the Alere Pima™ was used. 
 
ii. Blood safety tests  
Safety blood tests (Lactate dehydrogenase-LDH, Alkaline phosphatase-ALP, albumin, bilirubin, 
AST, ALT, creatinine) were performed in the research laboratory based at CISPOC using com-
mercial assays and analysers. 
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Table 4-1 Study procedures 
Study Phase  Screening Base-
line 
Follow up after start of TB treatment 
Study Visit  Screening 
Visit(s) 
[Visit 1]  
Baseline 
visit 
[Visit 2]  
Visit 
3  
Visit 
4  
Visit 
5  
Visit 
6  
Visit 
7  
Visit 
8  
Visit 
9  
Visit 
10  
Study Time 
Point  
Day -3 to -1  Day 0  
(day of TB 
treatment 
initiation)  
Wee
k 1  
(+/- 2 
days  
Week 
2  
(+/- 2 
days)  
Week 
4  
(+/- 2 
days)  
Week 
8  
(+/- 2 
days)  
Week 
12  
(+/- 2 
days)  
Week 
17  
(+/- 2 
days)  
Week 
26  
(+/- 2 
days)  
Week 
52  
(+/- 2 
days)  
Informed 
Consent  
X           
Spot Sputum  X  X  X  X  X  X  X  X  X   
Morning 
Sputum  
(X)  X  X  X  X  X  X  X  X   
Medical 
Question-
naire  
 X   X  X  X  X  X  X  X  
Clinical  
Examination  
 
X  
 
 X  X  X  X  X  X  X   
HIV- test 
(CD4)* 
 X          
Haematol-
ogy Chemis-
try 
C Reactive 
Protein 
Hep-B-test* 
 X     X   X  
Chest x-ray  X        X  
Spirometry, 
ECG and  
6-minutes 
walking test  
     X   X X 
Socio eco-
nomical 
question-
naire 
 X       X X 
St-George 
Respiratory 
Question-
naire 
 X    X   X X 
TB Treat-
ment adher-
ence  
 X  X  X  X  X  X  X  X   
 
* Performed only at baseline visit 
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g. Lung function assessment 
i. Spirometry and reversibility test 
Spirometry is a physiological test that measures how an individual inhales or exhales volumes of 
air as a function of the time [50]. When lung health is evaluated this test should be viewed as blood 
pressure is viewed during cardiovascular health is assessment. There are three basic measures in 
spirometry: volume, time and flow. 
In this test different lung volumes and capacities can be evaluated (see Table 4-2 and Figure 4-2). 
From standard normative values, we can conclude about the nature and extend of pulmonary ven-
tilation disorders. Sick subject values are compared to standard reference values from healthy pop-
ulation or to predict values from equations based on race, gender, age and height. 
 
Table 4-2 Spirometric measures 
Parameter Explanation 
Forced vital capacity (FVC) The maximum amount of air that can be exhaled when blowing 
out as fast as possible 
Forced expiratory volume in 1 s 
(FEV1) 
The amount of air that can be exhaled when blowing out as fast 
as possible in the first second 
Vital capacity (VC), The maximum amount of air that can be exhaled when blowing 
out as fast as possible 
FEV1/FVC ratio the ratio of FEV1 to FVC 
Peak expiratory flow (PEF) The maximal flow that can be exhaled when blowing out at a 
steady rate 
Forced expiratory flow, also known 
as mid-expiratory flow 
the rates at 25%, 50% and 75% FVC are given 
Inspiratory vital capacity (IVC) the maximum amount of air that can be inhaled after a full expi-
ration 
 
Figure 4-2 Standard lung volumes and capacities from a spirometer trace 
The solid black and grey arrows indicate lung volumes and capacities respectively 
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The Reversibility test consists in the use of a bronchodilator to evaluate if the obstruction is fixed 
or reversible. In COPD the obstruction is not reversible while in Asthma it is. 
Usually, for description of lung function abnormalities FEV1 and FVC are used [51]. Also, in this 
study, data analysis is mainly based on the values for FEV1, FVC and the FEV1/FVC ratio of a 
specific subject. 
 
ii. Device and test procedures 
Weight and height were measured using a mobile scale and stadiometer. Spirometry was be per-
formed using a handheld spirometer (EasyOne®ndd Medical Technologies, Inc), with individual-
use filtered one-way single-use mouthpieces (Spirrettes® and Medical Technologies, Inc)  
(Please see Spirometry and reversibility SOP in appendix 9). This device do not require regular 
calibration checks as it uses ultrasonic reading technology with high accuracy is used [52]. 
 
Figure 4-3 Easyone® cradle, spirometer and spirette. 
Source: ndd Medizintechnik AG Technoparkstrasse 1 CH-8005 Zurich 
 
The FVC expiratory manoeuvre used in our patients was performed in three phases : 1)Maximal 
inspiration, 2) a “blast” of exhalation and 3) complete exhalation to the end of the test [50]. All 
individuals performed a minimum of 3 and maximum of 8 curves. Test were performed with pa-
tient seated, wearing a nose clip with a disposable mouth piece. 
Readings for FVC and FEV1 were assessed for repeatability and reliability by the investigating 
physician or nurse and compared with the assessment performed by two clinical researchers - the 
site Principal Investigator (PI) and PI located at LMU. Study PIs received a spirometry training 
provided by a consultant pulmonologist from LMU, who further trained the clinical staff at the 
study site. To ensure data completeness and quality, regular monitoring of study procedures, in-
cluding spirometry. All data collected were performed by study PIs and clinical monitors from 
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LMU. ATS/ERS guidelines were followed for the measurement of ventilatory parameters and for 
quality control [23] 
 
 
Figure 4-4 Output from a spirometry test from EasyOne®ndd: A - flow volume curve, B – Time volume curve 
and Spirometry parameters 
 
iii. Interpretation and classification of spirometry results 
Both European Respiratory Society (ERS) and American Thoracic Society (ATS) recommends 
using the Lower limit of Normal (LLN) for analysis and interpretation of FEV1 and FVC although 
the percent of predicted was a previous most used methodology. 
Fixed ratios, were associated to false negative in younger populations and false positives in the 
elderly for example FEV1/FVC decreases with increase of age and height. This means more than 
20% of individuals are misclassified (false positives) [53]. 
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Table 4-3 Quality for spirometry curves Quality for spirometry curves 
Source: Walter et al. [54] 
Grade Quality criteria for FVC and FEV 
A >3 acceptable tests with repeatability within 0.150 L for age 2–6, 0.100 L, or 10% of 
highest value, whichever is greater 
B >2 acceptable tests with repeatability within 0.150 L for age 2–6, 0.100 L, or 10% of 
highest value, whichever is greater 
C >2 acceptable tests with repeatability within 0.200 L for age 2–6, 0.150 L, or 10% of 
highest value, whichever is greater 
D >2 acceptable tests with repeatability within 0.250 L for age 2–6, 0.200 L, or 10% of 
highest value, whichever is greater 
E One acceptable test 
F No acceptable tests 
 
Interpretation of spirometry results require a comparison with reference normal values, which con-
sider height, sex, age and sex/ethnicity to predict individual predicted lung function. Selected ref-
erence values need to be appropriate for the population being studied. The Global Lung Initiative 
(GLI) established global equations based on 74 000 individuals from 26 countries ages between 
3-95 years. Those reference values are applicable to Whites (applicable to Hispanics and Europe-
ans), African-Americans, North East Asians and South East Asians. Africans are not included in 
data used. Therefore, the recommendation is to use a composite equation for African population 
(also for other individuals not included in 4 main group or mixed). 
 
The selection of reference equations follows certain criteria: matching age- range, anthropometric, 
race/ethnic, socioeconomic and environmental characteristics between the subject being evaluated 
and the reference population from which the equations derived [55]. In this study spirometry, pre-
diction equations for South-African populations [56] were applied as reference standard to calcu-
late predicted values for FVC, FEV1 and residual z-scores. There are no South African equations 
for FEV1/FVC ratio, therefore the European Coal and Steel community equation was used with a 
correction factor of 10%. The type of ventilatory impairment was defined as follows:  
• Normal (No lung impairment): FEV1/FVC > LLN and FVC > LLN 
• Restriction: FEV1/FVC > LLN and FVC < LLN 
• Obstruction: FEV1/FVC < LLN and FVC > LLN 
• Mixed: FEV1/FVC < LLN and FVC < LLN 
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Yes 
No 
Yes 
No 
Yes 
No 
Table 4-4 Prediction equations for South African Black  
Source: Adapted from Guideline for office spirometry in adults 2012 [56] 
Sex Parameter Prediction equation RSD LLN 
Male FVC (l) 4.8H-0.02A-3.08 0.89 
Predicted value 
– (1.64 x RSD) 
FEV1(l) 2.9H-0.027-0.54 0.75 
Female FVC (l) 4.5H-0.023A-3.04 0.67 
FEV1(l) 3.4H-0.028A-1.87 0.64 
 
RSD = Residual Standard Deviation, LLN = Lower Limit of Normality (Lower 5th percentile), H = Height in meters, 
A = Age in years 
Table 4-5 European Community for Steel and Coal prediction equations (valid for ages 18 - 70 years) 
Source: Adapted from Guideline for office spirometry in adults 2012 [56] 
Sex Parameter Prediction equation RSD LLN 
Male FVC1/VC -0.1A + 87.21 11.8 Predicted value 
– (1.64 x RSD) Female FVC1/VC -0.19A + 89.10 10.7 
 
RSD = Residual Standard Deviation, LLN = Lower Limit of Normality (Lower 5th percentile), H = Height in meters, 
A = Age in years 
 
 
Figure 4-5 Algorithm for characterization of spirometry ventilatory defect based on the Lower Limit of Nor-
mality (LLN) 
The abnormal ventilatory function values were graded for severity (Table 4-6 Table 4-7) according 
to FVC for pulmonary restriction, FEV1 for pulmonary obstruction and FVC for mixed impair-
ment as FVC was the most affected parameter. Therefore, mild restriction or obstruction is defined 
as FVC or FEV1 greater or equal to 85% of LLN, moderate restriction or obstruction is defined as 
FEV1/FVC >
LLN
FVC> LLN
Normal
Restriction
FVC> LLN
Obstrucion
Mixed
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FVC or FEV1 between 85% and 55% of the LLN and severe restriction or obstruction is defined 
as FVC or FEV1 below 55% of LLN accordingly [57]. 
Table 4-6 Severity grading of spirometry results – if restrictive or mixed – based on % of LLN [57] 
FVC Restriction 
> 85% LLN Mild 
< 85% LLN and > 55% LLN Moderate 
< 55% LL Severe 
 
Table 4-7 Severity grading of spirometry results – if obstructive – based on % of LLN [57] 
FEV Restriction 
> 85% LLN Mild 
< 85% LLN and > 55% LLN Moderate 
< 55% LL Severe 
 
 
h. Functional capacity assessment 
i. 6 Minute Walk Test 
The 6-minute walking test (6MWT) is a self-paced test of the walking capacity. This a valid and 
reliable measure of exercise capacity in people with lung disease. The main outcomes of this test 
are: 6-minute walking distance (6MWD), peripheral capillary oxygen saturation (SPo2), heart and 
respiratory rate, dyspnoea and fatigue. 
It is a simple and inexpensive functional test. Functional walk tests either alone or in combination 
with other exercise tests have been validated in people with chronic cardiac and pulmonary dis-
ease, chronic obstructive pulmonary diseases and asthma, older adults with chronic heart failure, 
and in healthy, elderly adults [3]. Lower 6MWD is strongly associated with increased risk of Mor-
tality and hospitalization in patient with chronic respiratory patients [58]. 
The 6MWT is an example of a functional walk test that is practical and simple and only requires 
the ability to walk. The distance that a patient can walk on a flat surface in 6 minutes may be used 
as a generic one-time measure of functional status or as an outcome measure from a rehabilitation 
program [3]. 
Few studies have conducted this functional test in TB patients and have shown there was a signif-
icant difference in physical functional capacity between a group of normal older people and those 
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with TB sequelae [3]. After 6 months of treatment, the majority of participants had impaired func-
tional or Quality of Life scores compared to the average healthy control [17]. TB patients were 
request to walk as far as possible along a 30 meters straight track in a balcony, the distance was 
recorded in meters. Standardized instructions and encouragement were given during the test. Pa-
tient reported fatigue was reported was measured at the beginning and at the end of the test suing 
the Borg scale (Please see 6MWT SOP in appendix 10). This test was applied according to 
ATS/ERS guidelines [59]. 
Predicted walking distance in 6MWT are determined by reference equations. Those equations are 
affected by many factors like: sex, age, height, weight, race/ethnicity percentage of peak heart rate, 
and methodology used [58]. There is a lot of variation in the predicted 6MWD produced by dif-
ferent equations, local population generated and verified equations should be applied when possi-
ble. We were unable to identify equations generated for the Mozambican population. 
 
 
Figure 4-6 6-Minutes Walk Test track used - 30 meters 
 
ii. The Saint George Respiratory Questionnaire (SGRQ) 
The Saint George Respiratory Questionnaire (SGRQ) is a disease-specific instrument designed to 
measure impact on overall health, daily life, and perceived well-being in patients with obstructive 
airways disease. The questionnaire is composed by 50 items divided into 2 parts (3 components) 
Part I: Symptoms component (frequency and severity) and Part II: Activities that cause or are 
limited by breathlessness; impact components (social functioning, psychological disturbances re-
sulting from respiratory disease) [60]. 
The questionnaire scores range from 0 to 100, with higher scores indicating more limitations. In 
the study we used the Portuguese version of the questionnaire. 
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iii. Ethical considerations 
The study protocol was approved by Comité Nacional de Bioética para Saúde (CNBS), in Mozam-
bique (letter reference 274/CNBS/13) and the Ethics Commission of the Medical Faculty at LMU, 
in Germany before initiation of study. Each participant received a written information about the 
study. The consent was also be explained in the presence of an impartial literate witness, if the 
patient was illiterate. The informed consent sheet was provided in Portuguese language. The per-
son providing study information should ensure that the potential study participant understood the 
study procedures and also why the research is performed. 
The researchers of this study were committed to the recommendations guiding physicians in bio-
medical research involving human subjects issued by the World Medical Association Declaration 
of Helsinki, as last updated in 2013 in Fortaleza, Brazil [61]. 
All patient information was treated in a strictly confidential manner and anonymized by unique 
study Identification (ID) number. All files were stored at a secure, locked place to which only 
authorized study staff will had access. 
Patients and their community directly benefited from ‘being found’ with TB – a disease with sig-
nificant attendant morbidity and mortality. The risks related to study participation were considered 
low. The sampling procedures for sputum investigation and HIV-testing were part of standard 
care. Additional blood draws comprised a sample volume which did not pose any harm to the 
patients. 
Study patients were not be paid for their participation in the study. However, a financial compen-
sation for time and travel costs of 50,00 meticais (approximately 1,00 Euro) was provided to each 
participant in each study visit. 
 
iv. Data collection and management 
Data collection procedures in the study clinic and laboratories were described in SOPs or in Man-
ual of Procedures. 
The data management aspects of the study were defined in a separate Clinical Data Management 
Plan. Paper Case Report Forms (CRFs), as well as a web-based data management system (Open 
Clinica R) for on-site double data entry and data cleaning, was developed and supervised by the 
LMU data manager. All study documentation was stored on site for at least 3 years after publica-
tion. 
Study activities related to data generation, recording and management processes were continuously 
monitored through the Quality control (QC)/ Quality Assurance (QA) office at Cispoc. LMU staff 
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performed monitoring activities during their visits to the site, which checked both the procedures, 
CRFs and data points in the clinical data management system. 
 
v. Data analysis 
Data was analysed using Stata 15.0 Stata Corp, Texas, USA. The primary outcome was lung func-
tion as measured by spirometry at 52 weeks after initiation of TB treatment. 
Descriptive statistics was used to describe study population and characteristics. Persons’ Chi 
square test and Fisher exact test were used to compare proportions were adequate. The Wilcoxon 
Rank Sum, was used to compare medians. FVC and FEV1 Z-scores for TB patients, healthy vol-
unteers group and for the standard South African equations were used to construct kernel density 
plots. 
For the risk factor analyses three categories were considered: no impairment (standard category), 
mild impairment and moderate/severe impairment. For these categories a multinomial regression 
was performed to evaluate the association the association with different factor described in the 
literature. Like in a logistic regression we obtained Risk Ratios (RR) from the model for mild 
impairment and moderate/severe impairment categories, describing in this manner the influence 
of different risk factors [62]. 
 
III. Output II: Healthy volunteers lung function 
a. Study design and population 
A cross sectional study design was conducted in the INS TB Research Unit of INS in Maputo city, 
Mozambique between April 20th, and December 6th, 2017. In order to ensure that the healthy 
controls came from the same neighbourhood and environment like our TB cohort (output 1) we 
enrolled two healthy volunteers that came from the same household/neighbourhood per each study 
patient enrolled in the main MaTuTu study. Prior, we calculated that about 150-180 subjects 
should be enrolled to ensure that data can be used to generate standard normal values. 
Two healthy household or neighbourhood volunteers (one male and one female) were invited to 
take part in this study. These control subjects were screened for TB disease and respiratory symp-
toms. The participants benefited from lung function assessment and those found with abnormal 
function were referred to the nearest health center for care and treatment, therefore in our study 
healthy volunteers refers to the absence or acute or respiratory disease. 
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b. Eligibility criteria 
i. Inclusion criteria: 
• >/= 18 years old 
• Able and willing to give informed consent for study participation 
 
ii. Exclusion criteria: 
• Positive TB symptoms screening or acute/chronic respiratory disease 
• Suffering from a condition likely to lead to uncooperative behaviour e.g. psychiatric 
illness or alcoholism 
• Any contra-indication to perform spirometry or 6MWT  
40 
 
c. Study Activities 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-7 Study work flow and screening algorithm (diagram) 
a If participants did not consent to study procedures was not included; 
b Participants with contraindication for spirometry did not proceed perform the procedure; 
• Socio-demographic questionnaire: individual data like (date of birth, gender, ethnic-
ity, race), respiratory symptoms and disease history to exclude any previous acute or 
chronic lung disease (TB and chest symptoms, asthma and TB history). 
• Lung function test: Weight and height was measured using a mobile scale and stadi-
ometer. Spirometer was performed using a handheld spirometer (EasyOne®ndd Med-
ical Technologies, Inc), with individual-use filtered one-way single-use mouthpieces 
(Spirrettes® and Medical Technologies, Inc) (Please see Spirometry and reversibility 
SOP in appendix 9) 
Clinic visit: Informed consent a 
In those, who agree to participate: 
1. Demographic and respiratory disease Questionnaire b 
2. Spirometry 
3. 6-minute Walk Test 
Subject from TB cohort study identified at least two household or neigh-
borhood controls. TB patients contacts healthy participants and later pro-
vides contacts details to the clinic staff 
 
Clinic: Contact healthy volunteer to schedule a clinic visit 
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• 6MWT: Self-paced walking capacity was evaluated in a 30 meters course, heart rate, 
respiratory rate, blood pressure, capillary oxygen saturation was measured before and 
after the walk, the 6 minutes walked distance was the main outcome. 
(Detailed description of the procedures in page 30 and 35) 
 
 
Figure 4-8 Study procedures 
1 do not proceed to step 4 if any contraindication 
d. The establishment of reference equations in a population 
Many LMIC did not establish spirometry reference equations for their population. The equations 
are generally established from healthy populations with similar anthropometric and race/ethnicity. 
These countries rely on foreign equations with adjusting factors, therefore uncertainty derives from 
this strategy resulting in misdiagnosis [63]. 
Knudsen et al. [63] applied Mokoetle’s[64] and louw’s[65] for black South African man equations 
to Tanzanian population resulting in overestimation of FEV1. This can lead to false positives. 
These studies used workers cohorts, the healthy worker effect is one of the explanations for the 
finding higher lung volumes, other factor explanation can be associated to altitude and socioeco-
nomic status. 
 
 
Informed 
consent form
• If "Yes " proceed to 
next step
Socio-
demographic 
questionnaire
• Elegibility;
• Previous TB history;
• Socio demographic characteristics
• Assessment for spirometry and 6MWT1;
Spirometry test
6-minute 
Walk Test
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e. Ethical considerations 
The study protocol was approved by National Ethics (CNBS) in Mozambique (letter of reference 
449/CNBS/2016) and the Ethics Commission of the Medical Faculty at LMU, in Germany before 
initiation of study. 
Each participant received written information about the study. In addition, study staff provided an 
oral study description in the presence of an impartial literate witness if the patient was illiterate. 
The informed consent sheet was provided in Portuguese language. 
Study visit was performed after being scheduled via phone with potential study subjects. The study 
was committed to follow the recommendations guiding physicians in biomedical research involv-
ing human subjects issued by the World Medical Association Declaration of Helsinki 2013 [61]. 
All subjects’ information was treated in a strictly confidential manner and anonymized by unique 
study ID number. All files were stored at a secure and locked place to which only authorized study 
staff had access. 
The risks related to study participation was considered low. Spirometry is a non-invasive proce-
dure, although requiring some effort by the patient there are minimal risk related to it and study 
team is training on how to react if any of those happens (see Appendix 8 – MaTuTU Standard 
Operating Procedure - Spirometry and Reversibility Test). Study patients were not paid for their 
participation in the study. However, a financial compensation for time and travel costs of 100,00 
meticais (approximately 1,10 Euro) was provided to each participant. 
 
f. Data collection, management and analysis 
Data was primary collected in the study clinic using paper CRFs. Double data entry into Epi Info™ 
7.0 version 3.0 CDC, Atlanta, GA, USA, then QC and QA was performed and queries were gen-
erated and managed by CISPOC data manager. All study documentation was stored on site for at 
least 3 years after publication. 
The data was analysed using Stata 15.0 Stata Corp, Texas, USA. Descriptive statistics was used to 
describe study participants characteristics. FVC, FEV and the ratio was described in absolute val-
ues, percentage of predicted and Z-scores. For the comparison of proportions fisher exact tests or 
person’s chi square were used where appropriate, Wilcoxon Rank Sum was used to compare me-
dians. 
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5. RESULTS 
I. Output I 
a. Description of study population 
81 presumptive TB patients were screened for study participation, 12 were not enrolled for not 
meeting all legibility criteria. From the 69 enrolled participants four died before week 8, 65 par-
ticipants performed week 8 visit, five were not able to produce valid spirometry test. 
From the 65 participant that attended week 26, 3 were not able to produce valid spirometry test. 
One participant was lost to follow-up after week 26, from the 64 participants attending to the week 
52 visit 2 were no able to produce valid spirometry tests. Sixty-two study participants had a valid 
spirometry result at week 52 visit and consequently were included in the final analysis (Figure 
5-1). 
The Majority of study participant were males 67.7% (42/62). Participants median age was 29.5 
years (IQR 25-40), with 74.2 % (46/62) of participants ages below 40 years old. 62.3% (39/62) 
were coinfected with HIV, 46.2% (18/39) had severe immunodepression with a CD4 count below 
200 cells/µl. In Four participants this was their second episode of TB, four participants had Rifam-
picin resistance on the Xpert MTB/RIF. 
At the baseline visit the median haemoglobin in males was 11.7 g/dl (IQR 10.2-12.6) and 9.9 g/dl 
(IQR 9.45-11) in females, 83.9% of the participants had anaemia. C reactive Protein was increased 
(Median 76.8 mg/dl IQR 44-106.95) and only normal in one participant. 
The median BMI was 19.23 Kg/m2, 93.6% (58/62) of participant had culture conversion at week 
26, the overall affected lung median was 15% (IQR (15-20). 
Only male participants had history of smoking, 37% (23/62) of study participants had ever smoked, 
and about half of the study population (53.3%, 32/69) reported to regular consumption of alcohol 
critical amounts (Table 5-1). 
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Figure 5-11 Study flow diagram 
* Participants included in the final analyses. 
Participants no able to produce acceptable curves week 8 = 5, week 26 = 2 and week 52 = 2’ 
Source: Adapted from figure 1. Khosa et al, “Development of chronic lung impairment in Mozambican TB patients 
and associated risks” 
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Table 5-1 Baseline characteristics of TB cohort participants, included in final analysis 
Characteristic TB patients in final analysis (n=62) 
Sex 
     Male, % (n/N) 67.74 (42/62) 
Age 
     Median (IQR) 29.5 (25, 40) 
     < 40 years old, % (n/N) 74.19 (46/62) 
HIV-status 
     Positive, % (n/N) 62.90 (39/62) 
     CD4-cells < 200/µl, % (n/N) 46.15 (18/39) 
     CD4-cells 200-499/µl, % (n/N) 38.46 (15/39) 
     CD4-cells ≥ 500/µl, % (n/N) 15.38 (6/39) 
History of TB 
     Yes, % (n/N) 6.45 (4/62) 
RIF resistance (Xpert MTB/RIF) 
     Present, % (n/N) 6.45 (4/62) 
Haemoglobin 
     Median male, g/dl (IQR) 11.70 (10.2, 12.6) 
     Median female, g/dl (IQR) 9.90 (9.45, 11.00) 
Anaemia** 
     No, % (n/N) 16.13 (10/62) 
     Mild, % (n/N) 37.10 (23/62) 
     Moderate, % (n/N) 41.94 (26/62) 
     Severe, % (n/N) 4.84 (3/62) 
C-reactive protein (CRP)* 
     Median, mg/dl (IQR) 76.78 (44.0, 106.95) 
     <50 mg/dl, % (n/N) 31.03 (18/58) 
     51-100 mg/dl, % (n/N) 39.66 (23/58) 
     >100 mg/dl, % (n/N) 29.31 (17/58) 
BMI* 
     Median (IQR) 19.23 (17.63, 20.51) 
     <18.5, % (n/N) 40.98 (25/61) 
Culture conversion  
     Until week 8 56.45 (35/62) 
     Until week 26 93.55 (58/62) 
Overall affected lung** 
     Median % (IQR) 15 (15, 20) 
Smoking 
     Ever smoked, % (n/N) 37.10 (23/62) 
Pack Years*/** 
     None 50.00 (20/40)  
     <10 32.50 (13/40)  
     ≥10 17.50 (7/40)  
Alcohol consumption* 
     Ever alcohol, % (n/N) 77.42 (48/62) 
     Amount of alcohol, median, g/week (IQR)  80.0 (40, 240) 
     Critical alcohol consumption**, % (n/N) 53.33 (32/60) 
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*Available observations for CRP for 58 participants (normal range for CRP: 0.0 mg/dl-10 mg/dl, only one participant 
had a CRP value below 10mg/dl at baseline), available observations for BMI for 61 participants, available information 
for Pack Years for 60 participants, available information for amount of alcohol consumption for 60 participants. 
**definitions: 
- Anaemia, definition according to WHO, non-anaemia: 12mg/dl or higher (women) or 13 mg/dl or 
higher (men), mild: 11.0-11.9 g/dl (women) and 11.0-12.9 g/dl (men), moderate: 8.0g/dl-10.9g/dl 
(both sexes), severe: <8.0g/dl (both sexes) [66]. 
- X-ray scoring system for affected lung, according to Ralph et al. [22]. 
- Pack Years: numbers of years a person smoked 1 pack (20 cigarettes) per day, ≥10 pack years means 
that the respective study participant smoked an equivalent of one pack of cigarettes every day for 10 
years (e.g. 1 pack of cigarettes for 10 years, or 2 packs of cigarettes for 5 years, or ½ packs of ciga-
rettes for 20 years) at baseline study visit. 
- Critical alcohol consumption: in men (women) more than 60g (30g) alcohol per occasion of alcohol 
drinking and/or more than 150g (80g) alcohol per week, according to the International Alliance for 
Responsible Drinking for general population [67]. 
Source: Adapted from table 1, Khosa et al “Development of chronic lung impairment in Mozambican TB patients 
and associated risks” 
 
b. Spirometry results  
The spirometry results (FVC, FEV1 and FEV1/FVC-ratio) on the different study visits are sum-
marized separately for those with and without lung impairment in Table 5-2. The proportion of LI 
is 73.33% at week 8, declining to 67.74% at week 26 and 61.29% at week 52. The FVC and FEV1 
means (in litres) and percentages of predicted also show increasing trends during the follow up. 
There is no statistical difference between mean FVC at week 8 versus week 26 (P = 0.36) and 
week 26 versus week 52 (p = 0.23), but there is a significant statistical difference between week 8 
versus week 52 (p = 0.046). There is no statistical difference for the FEV1 mean between all study 
visits: week 8 and week 26, p = 0.46, week 26 and week 52, p = 0.34, and week 8 and week 52, 
p=0.12. 
On week 52 the mean FVC is 2.65 l (66.7% of predicted) in participants with LI versus 3.68 l 
(90% of predicted) in participants without LI. On the same week the FEV1 mean is 2.10 l (65.8% 
of predicted) in participants with LI versus 2.97 l (90.2% of predicted) in participants without lung 
impairment. The mean FEV1/FVC was approximately 80% for all groups in all study visits. 
We calculated the z-scores for FVC and FEV1 for all participants and study visits. As per defini-
tion, a z-score of -1.64 and below was considered as abnormal. In Figure 5-2, the z-scores for FVC 
and FEV1 at different study visits (week 8, 26 and 52) are shown for the 44 participants (a and b), 
who had abnormal FVC and FEV1 at week 8 and for the 16 participants with normal FVC and 
FEV1 at week 8. Both lung volumes (FVC, FEV1) were improving in the majority of participants 
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with abnormalities at week 8, but only few improve to normalization until week 52. Almost all 
women (red lines) with abnormal volumes at week 8 do not reach the normalization at week 52. 
Three participants with normal FVC at week 8 evolve with abnormal FVC until week 52, and four 
participants with normal FEV1 at week 8 develop abnormal FEV1 until week 52 (Figure 5-2 b and 
c). 
Table 5-2 Spirometry results of study participants at week 8, 26 and 52 after TB treatment initiation, in-
cluded in final analysis (N=62) 
  Week 8* Week 26 Week 52 
 
All 
(N=60) 
LI 
(N=44) 
No LI 
(N=16) 
All 
(N=62) 
LI 
(N=42) 
No LI 
(N=20) 
All 
(N=62) 
LI 
(N=38) 
No LI 
(N=24) 
% of N 100.00 73.33 26.67 100.00 67.67 32.26 100.00 61.33 38.67 
FVC in l 
(SD) 
2.77 
(0.78) 
2.48 
(0.61) 
3.55 
(0.66) 
2.90 
(0.78) 
2.56 
(0.60) 
3.62 
(0.62) 
3.05 
(0.78) 
2.65 
(0.59) 
3.68 
(0.60) 
FVC in % of 
pred. (SD) 
68.37 
(15.85) 
61.75 
(11.50) 
87.80 
(9.63) 
71.70 
(15.63) 
63.84 
(11.09) 
89.10 
(8.40) 
75.51 
(15.08) 
66.72 
(10.78) 
90.04 
(8.43) 
FVC z-score 
(SD)* 
-2.52 
(1.30) 
-3.07 
(0.98) 
-1.04 
(0.80) 
-2.25 
(1.24) 
-2.90 
(0.89) 
-0.93 
(0.70) 
-1.99 
(1.21) 
-2.71 
(0.85) 
-0.85 
(0.70) 
FEV1 in l 
(SD) 
2.25 
(0.70) 
2.01 
(0.57) 
2.88 
(0.64) 
2.32 
(0.69) 
2.01 
(0.52) 
2.97 
(0.55) 
2.44 
(0.70) 
2.10 
(0.53) 
2.97 
(0.60) 
FEV1 in % 
of pred. 
(SD) 
68.91 
(17.28) 
62.28 
(13.58) 
88.36 
(11.28) 
71.25 
(17.80) 
62.40 
(13.08) 
90.81 
(8.97) 
74.98 
(16.72) 
65.78 
(12.80) 
90.18 
(9.95) 
FEV1 z-
score (SD)* 
-2.26 
(1.28) 
-2.76 
(1.04) 
-0.92 
(0.87) 
-2.10 
(1.27) 
-2.74 
(0.91) 
-0.78 
(0.78) 
-1.85 
(1.21) 
-2.52 
(0.90) 
-0.79 
(0.81) 
Ratio 
(FEV1/FVC) 
81.09 
(9.67) 
81.17 
(10.49) 
80.86 
(7.22) 
79.39 
(8.65) 
78.22 
(9.60) 
81.86 
(5.66) 
79.44 
(7.95) 
78.91 
(9.27) 
80.27 
(5.29) 
FEV1/FVC 
z-score 
(SD)* 
1.07 
(1.35) 
1.07 
(1.50) 
1.09 
(0.88) 
0.81 
(1.18) 
0.63 
(1.33) 
1.20 
(0.70) 
0.82 
(1.09) 
0.72 
(1.29) 
1.00 
(0.66) 
 
SD= standard deviation, pred= predicted, LI= lung impairment, %= percentage, n= number of subjects in (sub-) 
group. There is a statistical evidence for a difference between the mean FVC at week 8 and week 52, p= 0.046, and 
no statistical difference between the mean FVC at week 8 and week 26, p=0.36, and the mean FVC at week 26 and 
week 52, p=0.23. There is no statistical difference for mean FEV1 between different study visits: week 8 and week 
26, p = 0.46, week 26 and week 52, p = 0.34, and week 8 and week 52, p=0.12. 
Source: Adapted from table 2, Khosa et al. “Development of chronic lung impairment in Mozambican TB patients 
and associated risks” 
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Figure 5-2 Trends of Z-scores over time for FVC (a) and FEV1 (b) of those participants with lung impairment at week 8 
(n=48) and for FVC (c) and FEV1 (d) of those participants without lung impairment at week 8 (n=16). 
Change in residual z-scores for FVC (a) and FEV1 (b) over time in study participants with lung impairment (resid-
ual z-score <-1.64) at week 8 and study participants without LI (residual z-score > 1.64) at week 8. Residual z-
scores (adjusted for sex, height and age) were calculated based on South African reference standard (and prediction 
equations) [56]. 
Source: Adapted from figure 2 and supplementary figure 2. Khosa et al. “Development of chronic lung impairment 
in Mozambican TB patients and associated risks” 
 
c. Type and severity of lung impairment 
Except one participant, who had obstructive ventilation impairment at week 52. All other study 
participants suffered from pulmonary restriction and no participants with mixed ventilatory im-
pairment during the study (Figure 5-3). The overall proportion of study participants with any 
lung impairment declined from week 8 to week 52, together with the proportion of participants 
with at least moderate or severe pulmonary restriction which decreased from 46% at week 8 to 
26% at week 52. 
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Figure 5-3 Proportions of types and severity grades of lung impairment at different study visits 
Week 8: N=60, 16 (26.67%) normal, 16 (26.67%) mild restriction, 16 (26.67%) moderate restriction, 11 (18.33%) 
severe restriction and 1 (1.67%) moderate obstruction. Week 26: N=62, 20 (32.36%) normal, 22 (35.48%) mild re-
striction, 9 (14.52%) moderate restriction, 9 (14.52%) severe restriction, 1 (1.61) mild obstruction and 1 (1.61%) 
moderate obstruction. Week 52: N=62, 24 (38.71%) normal, 21 (33.87%) mild restriction, 11 (17.74%) moderate 
restriction, 5 (8.06%) severe restriction, and 1 (1.61) mild obstruction. 
Source: Adapted from figure 3, Khosa et al. “Development of chronic lung impairment in Mozambican TB patients 
and associated risks” 
 
d. Risk factors for lung impairment  
Several risk factors were analysed for associations with LI at week 52. Female sex had a risk of 
developing moderate or severe LI five times (RRR = 5, p = 0.03) more than their male counterparts. 
HIV coinfection was not associated with LI, but between HIV coinfected patients a CD4 count 
above 200 cells/ µl were more likely to develop mild LI (RRR: 7.33, p = 0.02). 
The increase of one g/dl of haemoglobin reduced the relative risk for LI at week 52 by 31% (RRR 
= 0.69, p = 0.03) for mild lung impairment and by 37% (RRR = 0.61 p = 0.01) for moderate-severe 
LI. Surprisingly “ever smoking” was associated with reduced risk of 72% (RRR = 0.28, p = 0.02) 
for mild LI and 63% (RRR = 0.37, p = 0.04). Although not statistically significant smoking more 
than 10 pack years increased 10 times de risk for mild LI (RRR = 10, p = 0.11) and 7.5 times for 
moderate/ severe impairment (RRR = 7.5, p = 0.09). 
Age above 40 years old, C- reactive protein above 100 mg/dl were protective factor but not statis-
tically significant, from the other side low BMI, a delayed culture conversion and critical alcohol 
consumption increased the risk for abnormal lung function at week 52 and not statistically signif-
icant. 
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Table 5-3 Risk factor for lung impairment 
Baseline* Comparator* Severity grade 
of lung impair-
ment 
Risk Ra-
tio 
95% CI of 
RR 
p-value 
Male 
44 (63.77%) 
Female 
25 (36.23%) 
Mild 2.86 0.72, 11.37 0.14 
moderate/severe 5.00 1.17, 21.39 0.03 
Age < 40 years 
53 (76.81%) 
Age ≥ 40 years 
16 (23.19%) 
Mild 0.71 0.19, 2.70 0.62 
moderate/severe 0.81 0.19, 3.40 0.77 
BMI ≥ 18.5 
38 (55.07%) 
BMI < 18.5 
30 (43.48%) 
Mild 1.56 0.47, 5.19 0.47 
moderate/severe 1.46 0.39, 5.40 0.57 
HIV negative 
23 (33.33%) 
HIV positive 
46 (66.67%) 
Mild 1.05 0.32, 3.48 0.94 
moderate/severe 1.00 0.27, 3.69 1.00 
CD4 < 200/µl 
20 (28.99%) 
CD4 ≥ 200/µl 
26 (37.68%) 
Mild 7.33 1.38, 38.88 0.02 
moderate/severe 2.00 0.39, 10.31 0.41 
Culture conversion 
until week 8                        
35 (50.72%) 
No culture con-
version until week 
8             30 
(43.48%) 
Mild 1.39 0.43, 4.51 0.58 
moderate/severe 1.67 0.46, 6.01 0.43 
Culture conversion 
until week 26                      
61 (88.40%) 
No culture con-
version until week 
26             4 
(5.80%) 
Mild 3.63 0.35, 37.86 0.28 
moderate/se-
vere** 
- - - 
Never smoked 
(Males only) 
(No women smok-
ing) 20 (45.45%) 
Ever smoked 
(Males only) 
(No women smok-
ing) 24 (54.55%)  
Mild 0.22 0.05, 0.95 0.04 
moderate/severe 0.90 0.16, 4.92 0.90 
Never smoked 
(Males) 
(adjusted for PY) 
Ever smoked 
(Males) 
(adjusted for PY) 
Mild 0.28 0.09, 0.84 0.02 
moderate/severe 0.37 0.15, 0.95 0.04 
< 10 Pack Years*** 
13 (54.17%) 
≥ 10 Pack 
Years*** 
9 (37.50%) 
Mild 10.00 0.58, 171.2 0.11 
moderate/severe 7.50 0.72, 78.36 0.09 
No critical alcohol 
consumption****         
37 (53.62%) 
Critical alcohol 
consumption****    
15 (21.74%) 
Mild 1.00 0.22, 4.50 1.00 
moderate/severe 1.67 0.34, 8.10 0.53 
C-reactive protein 
(mg/dl) <100              
46 (66.67%) 
C-reactive protein 
(mg/dl) >100        
19 (27.53%) 
Mild 0.71 0.18, 2.76 0.63 
moderate/severe 0.97 0.24, 3.90 0.97 
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Haemoglobin, 1 g/dl increase at baseline Mild 0.69 0.49, 0.96 0.03 
moderate/severe 0.63 0.43, 0.91 0.01 
Overall affected lung, each 1% increase Mild 0.98 0.92, 1.05 0.58 
moderate/severe 1.02 0.95, 1.09 0.65 
 
Risk factor analysis using a multinomial regression model, comparing subjects with no impairment at week 52 (n= 
24) with those who have mild impairment (n=22) or moderate/severe impairment (n=16) at week 52. The absolute 
numbers and proportions of subjects in each individual stratum (baseline, comparator, mild lung impairment and 
moderate/severe lung impairment) can be found in appendix 7. 
*available observations for CRP in 58 participants, available observations for BMI in 61 participants, available infor-
mation for Pack Years in 60 participants, available information for amount of alcohol consumption for 60 participants. 
**no subject with moderate/severe lung impairment with no culture conversion at week 26 
***Pack Years (PY): for definition of Pack Years, refer to legend to table 1 
****critical alcohol consumption: for definition of critical alcohol consumption, refer to legend to table 1 
Source: Adapted from table 3, Khosa et al. “Development of chronic lung impairment in Mozambican TB patients 
and associated risks” 
 
e. Functional capacity and quality of life 
The 6MWT parameters (Peripheral capillary oxygen saturation – Spo2, fatigue and dyspnoea) after 
the walk show very small variation during the study visits. Spo2 was above 98%, reported fatigue 
below 2 and reported dyspnoea below 1 in all study visits in 75% of the walks performed. During 
the walk test in all the visit no patients interrupted the test or adverse event were registered, the 
tolerance for this test was very good from week 8 and improved along the study. 
Table 5-4 6-Minute Walk Test parameters after walk at week 8, 26 and 52 after TB treatment initiation, in-
cluded in final analysis (N=62) 
Parameters after walk Week 8 Week 26 Week 52 
Median - Spo2 (IQR) 98 (97, 99) 98 (98, 99) 99 (98, 99) 
Median fatigue (IQR)* 2 (1,3) 1 (1,2) 1 (0,1) 
Median Dyspnoea (IQR)* 1 (1,2) 1 (0.5,1) 0 (0,1) 
Median 6-Minute walk distance in 
meters (IQR) 
420 
(385.25, 456.25) 
429 
(396, 466.25) 
442 
(399.75, 485.50) 
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Spo2 – Median capillary oxygen saturation, IQR = Interquartile Range, *fatigue and dyspnoea were self-reported 
according to the Modified Borg Dyspnoea and Fatigue Scale (Scale 0-10) by patients after the walk ( See Appendix 
10 – MaTuTU Standard Operating Procedure - 6 Minute Walk Test) 
On week 8 the median distance travelled by participants was 420 meters (IQR 385.25 -456.25), 
the distance increased to 429 meters (IQR 396-466.25) on week 26 and 442 meters (IQR 399.75-
485.50) on week 52. 
 
Figure 5-4 6MWT distance Boxplot at different study visits 
The SGRQ total scores show a mean of 43.7 (SD: 19.2) at the baseline visit. On week 8 the total 
scores decrease to 21.1 (SD: 13.2) and on week 26 the score is 5.9 (SD: 6.4). The 3 components 
scores of the SGRQ are very similar in the visits. Due to the late implementation of the question-
naire not all participant responded to the SGRQ at baseline and week 8 visits. 
 
5-5 Saint George Respiratory Questionnaire (SGRQ) score (Symptoms, activity, impact and total) at different 
study visits 
Study visit Variable Mean SD 
Baseline  
(n= 26) 
Symptoms score 46.74 16.37 
Activity score 42.36 24.12 
Impact score 43.54 19.94 
Total score 43.70 19.21 
Week 8 
(n =42) 
Symptoms score 20.39 14.23 
Activity score 24.16 20.58 
Impact score 19.61 13.22 
Total score 21.16 13.18 
Week 26 
(n=62) 
Symptoms score 7.44 7.73 
Activity score 5.38 9.70 
Impact score 5.85 6.99 
Total score 5.85 6.41 
SD = Standard deviation. Portuguese version of SGRQ used, scale 0 (best) – 100 (worse)  
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II. Output II 
a. Description of study population 
In this cross-sectional study, lung function and demographic data were collected from 155 partic-
ipants. In this study, 40.64% were male, mean BMI was 25.6 Kg/m2, 53.55% of the participants 
had normal BMI (between 18,5 – 24.9 kg/m2). The mean age was 35.2 years with 67.74% with 
less than 40 years, 87.74% never smoked, 41.29% were single, 45,16% had education between 
grade 6-10, 26.45% reported being positive for HIV and 30.32% were never tested for HIV. At 
least 75.48% reported the use of charcoal to cook. 
 
Table 5-6 Characteristics of the healthy volunteers population 
Characteristics Male, n=63 
(40.64%) 
Female, n=92 
(59.35%) 
All, n=155 
Age (years) 
     Mean (SD) 33.83 (10.74) 36.13 (11.12) 35.20 (10.99) 
Height (meters) 
     Mean (SD) 1.67 (0.08) 1.60 (0.06) 1.63 (0.08) 
Weight (kgs) 
     Mean (SD) 65.52 (9.80) 69.24 (15.68) 67.73 (13.69) 
BMI (kg/m2) 
     Mean (SD) 23.43 (3.70) 26.95 (5.60) 25.52 (5.20) 
Age group 
     <30 years 27 (42.86%) 30 (32.61%) 57 (36.77%) 
     30-40 years 20 (31.75%) 28 (30.43%) 48 (30.97%) 
     >=40 years 16 (25.39%) 34 (39.96%) 50 (32.26%) 
BMI categories 
     Underweight 2 (3.17%) 2 (2.17%) 4 (2.58%) 
     Normal 45 (71.43%) 38 (41.30%) 83 (53.55%) 
     Pre-Obesity 11 (17.46%) 28 (30.43%) 38 (24.52%) 
     Obese 5 (7.94%) 24 (26.09%) 30 (19.35%) 
Smoking 
     Never Smoked 49 (77.78%) 87 (94.57%) 136 (87.74) 
     Past Smoker 8 (12.70%) 5 (5.43%) 13 (8.39%) 
     Current Smoker 6 (9.52%) 0 (0%) 6 (3.87%) 
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Marital Status 
     Single  25 (39.68%) 39 (42.39%) 64 (41.29%) 
     Married  11 (17.46%) 11 (11.96%) 22 (14.19%) 
     Living with 
spouse/partner 
25 (39.68%) 37 (40.22%) 
62 (40.00%) 
     Widowed 2 (3.17%) 5 (5.43%) 7 (4.52%) 
Education 
     Illiterate 0 (0%) 2 (2.17%) 2 (1.29%) 
     Grades 1-5 5 (7.94%) 24 (26.09%) 29 (18.71%) 
     Grades 6-10 27 (42.86%) 43 (46.74%) 70 (45.16%) 
     Grades 11-12 17 (26.98%) 20 (21.74%) 37 (23.87%) 
     Vocational 8 (12.70%) 2 (2.17%) 10 (6.45%) 
     University 6 (9.52%) 1 (1.09%) 7 (4.52%) 
Self-reported HIV status 
     Unknow/never tested 26 (41.27) 21 (22.83) 47 (30,32%) 
     Negative 27 (42.86) 40 (43.48) 67 (43,23) 
     Positive 10 (15.87) 31 (33,69) 41 (26,45) 
Worked in mines 
     No 61 (96.83%) 92 (100%) 153 (98.71%) 
     Yes 2 (3.17%) 0 (0%) 2 (1.29%) 
Cooking Material (More than one options possible) 
     Electricity 26 (41.27%) 30 (32.61%) 56 (36.13%) 
     Gas 25 (39.68%) 32 (34.78%) 57 (36.77%) 
     Charcoal 48 (76.19%) 69 (75.00%) 117 (75.48%) 
     Wood 6 (9.52%) 14 (15.22%) 20 (12.90%) 
 
SD= standard deviation, Continuous risk factors have the mean values and range, stratified for sex as well as for the 
combined sample. We consider only samples having a valid spirometry outcome with an observed FVC and FEV1 
for the risk factor summary, which is only 155 out of 212 observed individuals. For categorical risk factors the 
counts segregated by sex is reported; for the combined sample, we report the proportion belonging to each of the 
observed categories in addition to the count. Cooking material does not have mutually exclusive categories. HIV 
status is missing for 47 samples out of the considered 155 samples for statistical analysis. 
Source: Adapted Ivanova & Khosa et al. “Lung function testing and predictive equations in adult population in Ma-
puto, Mozambique” 
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b. Spirometry results  
In Table 5-7 spirometry results (FVC, FEV1 and FEV1/FVC ratio) are summarized segregated by 
sex. Male participants presented higher volumes, mean FVC of 3.77l (90.8% of predicted) and 
FEV1 of 3.12l (91.2% of predicted) compared to females with FVC of 2.94l (88.6% of predicted) 
and FEV1 of 2.43l (95.5% of predicted). The mean FEV1/FVC ratio was 81% in both groups. 
Table 5-7 Spirometry results of healthy volunteers controls (N=155) 
 Male, n=63 Female, n=92 All, n=155 
FVC in l 
(SD) 
3.77 
(0.69) 
2.93 
(0.47) 
3.27 
(0.70) 
FVC in % of pred. 
(SD) 
90.82 
(11.43) 
88.38 
(12.04) 
89.37 
(11.82) 
FEV1 in l 
(SD) 
3.12 
(0.67) 
2.43 
(0.42) 
2.71 
(0.63) 
FEV1 in % of pred. 
(SD) 
91.28 
(13.69) 
95.53 
(13.02) 
93.80 
(13.41) 
FEV1/FVC Ratio 
(SD) 
82.48 
(6.42) 
82.93 
6.62) 
82.75 
6.52) 
SD= standard deviation, pred= predicted, %= percentage, n= number of subjects in (sub-) group. 
Predicted values were calculated based on South African reference standard (and prediction equations) [56]. 
Source: Adapted Ivanova & Khosa et al. “Lung function testing and predictive equations in adult population in Ma-
puto, Mozambique” 
 
c. Type and severity of lung impairment 
In our healthy volunteers control population, 20% (31/155) of the participants had abnormal lung 
function test. Restriction was the most predominant type of impairment 19,35% (30/155) overall, 
followed by obstruction in one female participant (0.65% overall) and no cases of mixed ventila-
tory impairment. In this study 23.91% (22/92) of females had restriction compared to 12,70% 
(8/63) of males. In general, women were more likely to suffer from lung impairment compared to 
men. The severity of impairment is similar in both sexes. 
  
57 
 
Table 5-8 Proportions of types of Lung impairment 
 
 
 
Source: Adapted Ivanova & Khosa et al. “Lung function testing and predictive equations in adult population in Ma-
puto, Mozambique” 
 
 
Figure 5-5 Proportions of types of Lung impairment a) all study participants b) Male participants c) Female 
participants 
Type of lung impairment in a) all b) Male and c) Female 
 
All but one case (mild obstruction in a female participant) are of mild and moderate impairment. 
The severity of impairment is describe in Table 5-9 and Table 5-10. 
 
 
87%
13%
0%
Normal Restriction Obstruction
75%
24%
1%
Normal Restriction Obstruction
Type of impairment Male, n=63 Female, n=92 All, n=155 
Normal (%) 55 (87.30%) 69 (75.00%) 124 (80.00%) 
Restriction (%) 8 (12.70%) 22 (23.91%) 30 (19.35%) 
Obstruction (%) 0 (0.00%) 1 (1.09%) 1 (0.65%) 
80%
19%
1%
Normal Restriction Obstruction
b) Male c) Female 
a) all 
58 
 
Table 5-9 Severity of restriction 
 Male, n=8 Female, n=22 All, n=30 
Mild 6 16 22 (73.33%) 
Moderate 2 6 8 (26.67%) 
Severity in case of lung impairment according to z scores obtained by comparing to the health volunteer predictions 
for the South African healthy population. 
Table 5-10 Severity of obstruction 
 Male, n=0 Female, n=1 All, n=1 
Mild 0 1 1 (100.00%) 
Severity in case of lung impairment according to z scores obtained by comparing to the health volunteer predictions 
for the South African healthy population. 
 
d. Functional capacity 
The healthy volunteers participants travelled a distance of 441 meters (IQR 405-480.50). The 
Spo2, fatigue and dyspnoea scores were with normal ranges in this group (Table 5-11). No inter-
ruptions or adverse events were registered during the walks. 
 
Table 5-11Minute Walk Test parameters after walk (N=155) 
Parameters Median periph-
eral capillary 
oxygen satura-
tion - Spo2 
(IQR) 
Median fatigue 
(IQR)* 
Median Dysp-
noea (IQR)* 
Median 6-Mi-
nute walk dis-
tance in meters 
(IQR) 
 99 (99-99) 1 (0-2) 0 (0-0.5) 441 (405, 480.5) 
 
IQR = Interquartile Range, *fatigue and dyspnoea were self-reported according to the Modified Borg Dyspnoea and 
Fatigue Scale (Scale 0-10) by patients after the walk (See Appendix 10 – MaTuTU Standard Operating Procedure - 
6 Minute Walk Test) 
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III. Output III 
a. Comparison of TB patient versus healthy participants 
The main characteristics of the TB cohort versus healthy participants are summarized in Table 
5-12. There was a significant lower proportion of men (40.65% versus 67.7%), smokers (12.3% 
versus 37.1%) and HIV-positives (26.5%, self-reported, versus 62.9%) among the healthy con-
trols, p<0.001. The age median and proportion of participants younger than 40 years old was sim-
ilar in both groups (33.9 years versus 29.5 years, p = 0.13 and 67.74% versus 74.19%, p = 0.35). 
 
Table 5-12 Baseline characteristics of TB cohort and healthy volunteers 
Characteristic TB cohort 
(N=62) 
Healthy volunteers 
(N=155) 
p-value** 
Sex 
     Male, % (n/N) 67.74 (42/62) 40.65 (63/155) <0.001 
Age 
median (IQR) 29.5 (25, 40) 33.9 (26, 42) 0.13*** 
     < 40 years old, % (n/N) 74.19 (46/62) 67.74 (105/155) 0.35 
HIV-status 
     Positive, % (n/N) 62.90 (39/62) 26.45 (41/155) * <0.001 
History of TB 
     Yes, % (n/N) 6.45 (4/62) 0.00 (0/155) 0.001 
Ever smoked 
     Yes, % (n/N) 37.10 (23/62) 12.26 (19/155) <0.001 
 
*missing/unknown self-reported HIV-status in 47 (47 of 155, 30.32%) subjects of healthy volunteers, **p-value for 
difference in proportions, *** rank sum test  
 
We generated density distribution of adjusted z-scores of FVC and FEV1 for the TB patients at 
week 52 (red), healthy participants (green) and the South African reference standard (black). The 
TB cohort demonstrated a much more pronounced shift of both curves (FVC and FEV1) to lower 
z-scores when compared to the healthy group and there is also a large left-side tail below a z-score 
of -1.64, which represents a higher proportion of subjects with abnormal lung function. 
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Figure 5-6 Residual Z-scores density plots for standard population (black - south Africa reference popula-
tion), healthy control (green) and week 52 Post-TB (red). a)-FVC and b)-FEV1 
Source: Adapted from table 3, Khosa et al. “Development of chronic lung impairment in Mozambican TB patients 
and associated risks” 
 
Even after improvement in FVC and FEV z scores from week 8 to week 52 after treatment for TB, 
the z scores are still statistically significantly lower than the controls (p<0.0001 for FVC Z scores 
and p <0.0001 for FEV1 Z scores). As expected from the predominant type of lung impairment 
the FVC have a greater affection than FEV1 when controls are compared to week 52 (Figure 5-7 
and Figure 5-8). 
 
Figure 5-7 FVC Z Scores Boxplot 
Comparison of FVC Z scores using the global test (Kruskal Wallis) followed by the post hoc analysis using Dunn’s 
test for multiple comparison. There is a statistical evidence for a difference between the mean FVC at week 52 and 
healthy volunteers, p< 0.0001. 
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Figure 5-8 FEV Z Scores Boxplot 
Comparison of FEV1 Z scores using the global test (Kruskal Wallis) followed by the post hoc analysis using Dunn’s 
test for multiple comparison. There is a statistical evidence for a difference between the mean FEV1 Z scores at at 
week 52 and healthy volunteers, p< 0.0001. 
 
The Comparison of median 6MWT distance using the global test (Kruskal Wallis) there is no 
statistical difference be-tween different study visits and healthy participants: week 8 (n=58) and 
healthy participants, p. adjusted = 0.053, week 26 (n=60) and non TB participants, p. adjusted = 
0.232, and week 52 (n=60) and healthy participants, p. adjusted = 0.690. 
 
 
Figure 5-9 Box plot of 6-minute distance in TB patients (all study visits) and healthy participants  
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b. Comparison of references equations for the Mozambican population 
As discussed in chapter iii the GLI worldwide equations do not include African populations and 
we did not find studies that establish equations for Mozambican population. From this healthy 
controls Ivanova and Khosa et al (unpublished) established reference equations applicable for this 
specific region of Mozambique. 
The Table 5-13 Equation established in South African population (Workers cohort) are shown 
together with those from the healthy Mozambican cohort. 
 
Table 5-13 Comparison of equations based on South African and Mozambican volunteers 
Outcome (Sex spe-
cific) 
South African population Mozambique population 
FVC Males -3.08-0.024*Age+4.8*Height -2.268-0.020*Age + 4.000* Height 
FVC Females -3.04-0.023*Age+4.5*Height -2.750-0.020*Age + 4.000* Height 
FEV1 Males -0.54-0.027*Age+2.9*Height -1.845-0.025*Age + 3.467* Height 
FEV1 Females -1.87-0.028*Age+3.4*Height -2.223-0.025*Age + 3.467* Height 
Source: Adapted Ivanova & Khosa et al. “Lung function testing and predictive equations in adult population in Ma-
puto, Mozambique” 
 
The equations derived from the healthy Mozambican participants have different coefficients 
when compared to the south African equations, this will lead to different diagnosis and classifi-
cation of impairment between the equations. In regards to FVC equations Mozambique (MZ) 
equations have a smaller coefficient for height and bigger coefficient for age when compared to 
South Africa (SA) equations. For FEV1 MZ equations have both coefficients for height and age 
higher. 
 
We have used the MZ equations above to reassess impairment, type of impairment in the TB cohort 
and compared the outcome when using the south African reference equations (different method-
ology was used for the determination of LI). It is clear that there is some misclassification with 
the South African reference equations leading to more Lung imparity and severity. Using the non-
TB participants equations 13/33 cases of restriction (SA equations) are classified as normal (MZ 
equations). In terms of severity 13/22 mild impairment cases (SA equations) change to no impair-
ment (MZ equations) and 7/22 mild impairment (SA equations) change to moderate/severe cases. 
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The agreement on the mild cases is only in two cases. 
From this analysis the proportion of lung impairment decreases from 61.29% to 43.55%, decreas-
ing the overall proportion of mild cases and increasing the overall and relative proportion of mod-
erate/severe cases (Additional 6 cases). Therefore, we can speculate that TB is responsible for 
around 40% of cases of lung impairment in this community. 
 
Table 5-14 Lung impairment type misclassification when compared to the Mozambican non-TB cohort refe-
rence equations to the South African reference equations 
 
Predictions (South African MLR) 
 
Impairment 
Outcome 
Normal Obstruction Restriction Mixed 
Predictions 
(Mozambique in-
dividual 
(FEV1/FVC) 
MLR) 
Normal 22 0 13 0 
Obstruction 0 1 0 1 
Restriction 0 0 20 0 
Mixed 0 0 0 4 
 
Table 5-15 Lung impairment severity misclassification when compared to the Mozambican non-TB cohort 
reference equations to the South African reference equations 
  South African healthy volunteer standards 
 
Impairment sever-
ity 
No impairment Mild impairment Moderate/severe im-
pairment 
Mozambique 
healthy volun-
teer standards 
No impairment 22 13 0 
Mild impairment 1 2 1 
Moderate/severe 
impairment 
0 7 15 
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6. DISCUSSION 
IV. Output I 
This is the first report describing lung impairment in TB patients from Mozambique. Our results 
showed that 12 months after TB treatment initiation more than half (61%) of TB patients presented 
lung impairment and even a quarter of them had moderate or severe impairment. This finding is 
in line with that of similar studies from African countries: two studies conducted in Benin and 
Botswana the prevalence of lung impairment were about 45% and 56%, respectively [68, 69], in a 
study from Tanzania the prevalence of LI was 74% [7]. Also study data from Asia [17] and Amer-
ica [2, 18] indicate, that on average half of previous TB patients show abnormalities in spirometry. 
Smaller differences in proportions among these studies (about 10%) can –most likely- be explained 
by differences in data analysis, e.g. selection of best spirometry result, selection of reference values 
(see below) and threshold for abnormality. 
However, in many studies, the majority –or at least a relevant proportion- of post TB patients 
presented with pulmonary obstruction, while in our study almost all patients had pulmonary re-
striction, represented by a low FVC but normal FEV1/FVC ratio. The different pattern may result 
from the presence of different background risk factors, e.g., environmental or indoor air pollution, 
smoking behaviour in communities, lung infections in childhood, etc., in the different setting the 
study were performed, including genetic factors determining the immune response pathway [33]. 
Further age per se is a risk factor for chronic lung diseases and also COPD. This might also explain 
why we saw almost no obstructive ventilation impairment in our relatively young patients with a 
median age of about 30 years. 
Due to a prospective study design, we were able to measure FEV1 and FVC during and after TB 
treatment. Like in the few other prospective studies [2, 17], an increase of both parameters could 
be observed over time in most subjects, although this improvement was only small and borderline 
significant. Importantly, the majority of subjects and all women with lung impairment at week 8 
still had lung impairment at week 52. Further, only very few patients with normal values for FEV1 
and FVC and week 8 (three and four, respectively), showed lung impairment later in the follow 
up, at week 52. This finding indicates that LI is usually developing early during the course of 
active TB disease, e.g. before treatment start or early during treatment and that a large part of the 
disease is not significantly reversible under TB treatment. Further research studies are needed in 
which lung function is measured before treatment start or early during treatment (e.g., until week 
4) in order to further define the best timepoint for potential therapeutic interventions which are 
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aiming for preservation of lung function, such as host directed therapies or immune-modulation. 
These types of treatment are currently not available, however, several trials are currently ongoing 
(not published data) in order to assess such treatments in addition to anti-microbial treatment of 
TB. 
 
In our study, female sex was associated with lung impairment. This finding is surprising as in 
many other studies on microbiological TB outcome or lung function as outcome men showed an 
elevated risk for poor outcome categories [7]. Often, this association was confounded by additional 
risk behaviour such as alcohol drinking and smoking. As female participants did not smoke and 
were less likely to drink critical amounts of alcohol, other factors, such as indoor air pollution, 
access to health care or immunological/hormonal factors, might be contributing to the higher risk 
for LI in women compared to men. 
Of note, in our study, smoking and alcohol consumption per se were no risk factors for LI. This 
observation might be based on a healthy smoker/drinker effect, when either subjects with a good 
physical condition or those who have access or can afford the consumption of these stimulants do 
not develop lung impairment due to the presence of other, protective, factors. This thinking is 
further supported by the finding that the consumption of higher amounts of tobacco (>10PY) and 
alcohol (critical alcohol consumption) showed a positive association with LI, indicating that at a 
certain threshold the “healthy smoker effect” is not compensating the actual damage of tobacco 
and or alcohol to the lung. It is commonly known and was shown by several studies that alcohol 
consumption and smoking can lead to poor TB outcomes. Also with regards to lung outcome, 
smoking was shown to be a risk factor in several studies worldwide [7, 18], although this could 
not be confirmed in few other studies from Africa and Asia [17, 21, 68]. Alcohol, was so far not 
assessed as risk factor for lung outcome. However, it is known that alcohol can impair the immune 
response of a subject and thus, could lead via this pathway to increased lung damage in TB patients 
[70]. However, especially with regards to smoking and alcohol drinking as risk factors for post TB 
LI, it cannot be excluded that in a certain proportion of study participants, a certain level of lung 
impairment was existing before active TB disease was developed (see below). A positive HIV-
status was not a risk factor for lung impairment after TB. This is in line with few other studies 
from Africa [68] but contrary to what Manji et al found [7]. However, those HIV-positives with 
CD4 higher than 200 cels/ul at baseline visit had an higher risk for post TB restriction compared 
to those with lower CD4 count. This effect was already observed in another study by Ravimohan 
et al [69]. Interestingly, anaemia was a risk factor in this study. Iron metabolism is closely related 
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to pro inflammatory status [71], and several inflammatory diseases like TB are related to a shift of 
iron into the bone narrow macrophages, which could also be the reason for anaemia [72] in our 
study participants, who developed LI after TB. 
In the absence of a local spirometry reference standard, we used South African prediction equa-
tions as basis for the analysis of spirometry data. The spirometry results of the healthy volunteers 
(see discussion below) indicate that a major part of the observed LI in TB patients was very likely 
associated with TB. Although the healthy volunteers were on average 5 years older than the TB 
patients, only about 20% of them had abnormal lung parameters and mostly of mild grade only.  
One limitation of our study was the sample size, which prevented a more in dept analysis of some 
other risk factors like time to TB diagnosis or ART initiation in HIV-positives, TB severity on 
chest x-ray or microbiological markers such as bacterial load. Also, the risk factors shown in this 
study could not be controlled for bias such as confounding or effect modification. Further, the 
small samples size and also the limitation of study subjects to one neighbourhood only does not 
allow the generalization of our findings to the general population of TB patients in Mozambique. 
 
V. Output II 
In our study, the healthy volunteers were in majority females, had a higher BMI, lower HIV rates 
and less history of smoking when compared to TB participants. There are no significant differences 
related to age and proportion of patients below 40 years old. Individuals with history of TB were 
non eligible for the study. 
One in every five healthy participant had LI, not surprisingly restriction was the most prevalent 
type of LI and more prominent in females. Participants are susceptible to other lung injuries factors 
like childhood respiratory infection, indoor air pollution and air pollution. Three in each four par-
ticipants referred the use of charcoal for cooking, females might be more exposed to the fumes 
leading to more severe LI. 
The South African prediction equation are derived from a healthy worker; therefore, a healthy 
worker effect might be responsible for higher rates of LI in our healthy volunteers as working 
individual usually have better lung function [65, 73]. Further, reference values are usually derived 
from non-smokers. Although only 12.3% of our participants were smokers, this might be another 
reason for impaired lung function in our healthy volunteers. Finally, as restriction was the prevail-
ing lung function impairment found in the healthy volunteers, it is also thinkable, that the South 
African standard cannot be applied to Mozambican population due to physiologic differences that 
lead to a smaller total lung capacity in Mozambicans compared to South Africans. 
67 
 
Finally, we have used equations derived from the healthy volunteers to access the potential mis-
classification derived from the use of South African equations, i.e. in case the South African stand-
ard cannot be applied to Mozambicans. Having in account that the control group differ mainly 
from the TB participant by the inexistence of history of TB, the difference in prevalence of LI 
might be attributed to TB. 
Using the MZ equations generated from the healthy volunteers there is not a significant decrease 
in the proportion or type of lung impairment. 
The main type of lung impairment, restriction, does not change when healthy volunteers lung func-
tion is assessed, leading the conclusion that other lung insults lead to this specific lung remodela-
tion. 
Our study had some limitations: 1/ HIV status was self-reported leading to missing data although 
this was not a relevant risk factor in our TB cohort, 2/ Exposure to biomass fuel and other lung 
insults was not collected in a quantifiable manner and 3/Smoker were not excluded and absence 
of lung disease not ascertained via imagiology (e.g Xray). 
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7. CONCLUSION 
 
1. More than half of those cured from TB on their first episode still present with lung impair-
ment 52 weeks after TB diagnosis. The majority had restrictive lung impairment and in 
25% the grade of impairment was severe or moderate. The pattern of lung impairment in 
different study populations most likely depends on several risk factors, including indoor 
air pollution or other aggressors such as childhood respiratory infections or dusty environ-
ments. It might also be that the genetic background also plays a relevant role in this context. 
In our setting, female gender, the severity of HIV related immune-depression and low hae-
moglobin are important risk factors for lung impairment. 
 
2. South African prediction equations might not be completely applicable in Mozambican 
population. In addition, other factors besides TB related may drive the occurrence of re-
strictive pattern of lung impairment, and being more prevalent in female participants. 
 
3. There is a huge effort to control and end TB, however, Post TB Chronic lung disease 
(PTBLD) and also the resulting burden on quality of life is overlooked. Although the early 
diagnosis and treatment might lead to fewer sequel[6], our data also support the thinking 
that additional risk factors can lead to LI which could be controlled or treated. New guide-
lines for diagnosis and treatment of PTBLD are urgently needed in order to reduce TB 
related morbidity.  For now, for many TB patients the end of anti-microbiological treatment 
is just the beginning of a long journey of suffering and even early death in some cases[2, 
18]. 
 
4. In high TB burden settings, chronic pulmonary services are scarce and former TB patients 
presents with symptoms similar to their previous episodes. The health professional may 
misinterpret as another episode of TB treatment with consequent treatment. Some of those 
cases are indeed cases of PTBLD. Therefore, our work shows how closely pulmonary in-
fectious diseases and non-communicable diseases (NCDs) of the lung can be interrelated. 
More efforts in the development of pulmonary health services are needed in Mozambique 
in order to improve long-term lung outcome in TB patients.  
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8. RECOMMENDATIONS 
 
There is a need of more studies on lung outcome in PTB patients and a necessity of inte-
grated pulmonary function testing and rehabilitation during and after TB treatment. Those 
studies should focus on: 
• Increase the knowledge on prevalence, type and severity of PTBLD; 
• Understand the underlying pathophysiological pathways and risk factors in order 
to develop new interventions; 
• Trials on preventive therapies (host directed therapies) and supportive/ sympto-
matic therapies including rehabilitation. 
 
Additional studies also are needed to establish reference equation applicable to the Mozam-
bican population. 
 
Spirometry and inhalers should be available at TB treatment center to support diagnosis 
and treatment of PTBLD. Respiratory and rehabilitation should be available for TB pa-
tients. Further studies are needed to understand the lung remodulation post TB, the risk 
factors and measures to improve the lung function during TB treatment. 
 
Finally, new drug and new regimens should include lung function evaluation in order to 
identify drug-regimens with better lung outcomes. 
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VI. Appendix 6 – TB burden in Mozambique (source: World TB Report 
2018[1]) 
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VII. Appendix 7 – Supplementary table 1: Distribution of risk factors in par-
ticipants from TB cohort without and with LI (and with mild or moder-
ate/severe LI among those with LI) 
 
Risk factor, total N= 62 Total No LI,  
% (n) 
 
(N=24) 
Any LI,  
% (n) 
 
(N=38) 
Mild LI, 
(n) 
 
(N=22) 
Moderate/ 
severe LI,  
(n) 
(N=16) 
Sex       
     Male 42 47.62 (20) 52.38 (22) 14 8 
     Female 20 20.00 (4) 80.00 (16) 8 8 
Age      
     < 40 years old  46 36.96 (17) 63.04 (29) 17 12 
     ≥40 years old  16 43.75 (7) 56.25 (9) 5 4 
BMI*      
     < 18.5 25 32 (8) 68 (17) 10 7 
     ≥ 18.5 36 41.57 (15) 58.33 (21) 12 9 
HIV-status      
     Positive 39 38.46 (15) 61.54 (24) 14 10 
     CD4- cells < 200/µl 18 55.56 (10) 44.44 (8) 3 5 
     CD4- cells ≥ 200/µl 21 23.81 (5) 76.19 (16) 11 5 
     Negative 23 39.13 (9) 60.87 (14) 8 6 
Culture Conversion at 
week 8 
     
     Yes  35 42.86 (15) 57.14 (20) 12 8 
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     No  27 33.33 (9) 66.67 (18) 10 8 
Culture conversion at 
week 26 
     
     Yes  58 39.66 (23) 60.34 (35) 19 16 
     No  4 25 (1) 75.00 (3) 3 - 
Ever smoked      
     Yes  22 59.09 (13) 40.91 (9) 4 5 
     No  40 27.50 (11) 72.50 (29) 18 11 
Pack Years*, **      
      <10 13  76.92 (10) 23.08 (3) 1 2 
      ≥10 7 28.57 (2) 71.43 (5) 2 3 
Critical alcohol con-
sumption*,** 
     
     Yes 32 43.75 (14) 56.25 (18) 8 10 
     No  30 33.33 (10) 66.67 (20) 14 6 
C-reactive protein*       
     <100 mg/dl 41 36.59 (15) 63.41 (26) 15 11 
     ≥100 mg/dl 17 41.18 (7) 58.82 (10) 5 5 
Hemoglobin       
     Median male, g/dl 
(IQR) 
42 11.95 
(11.12, 
12.82) 
11.15 (9.75, 
12.55) 
11.45 
(10.10,12.60) 
10.5 
(9.38,12.18) 
     Median female, g/dl 
(IQR) 
20 11.1 
(10.62, 
12.00) 
9.8 
(9.08,10.78) 
9.7 (8.10, 
10.78) 
9.8 (9.48, 
10.70) 
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Overall affected lung at 
baseline, Ralph et al.**  
     
     Median, % (IQR) 62 17.5 
(15,20) 
15 (13, 25) 15 (10,25) 20 (15, 
21.25) 
 
Legend to supplementary table 2: 
*missing observations: CRP for 4 participants, BMI for 1 participant, Pack Years (PY) for 2 participants, amount of 
alcohol consumption for 2 participants. 
**definitions: 
- Anaemia, definition according to WHO, non-anaemia: 12mg/dl or higher (women) or 13 mg/dl or higher 
(men), mild: 11.0-11.9 g/dl (women) and 11.0-12.9 g/dl (men), moderate: 8.0g/dl-10.9g/dl (both sexes), se-
vere: <8.0g/dl (both sexes)[66]. 
- X-ray scoring system for affected lung, according to Ralph et al [74].  
- Pack Years: numbers of years a person smoked 1 pack (20 cigarettes) per day, ≥10 pack years means that the 
respective study participant smoked an equivalent of one pack of cigarettes every day for 10 years (e.g. 1 
pack of cigarettes for 10 years, or 2 packs of cigarettes for 5 years, or ½ packs of cigarettes for 20 years) at 
baseline study visit. 
- Critical alcohol consumption: in men (women) more than 60g (30g) alcohol per occasion of alcohol drinking 
and/or more than 150g (80g) alcohol per week, according to the International Alliance for Responsible Drink-
ing for general population[67] 
Source: Adapted from supplementary table 2, Khosa et al. “Development of chronic lung impairment in Mozambi-
can TB patients and associated risk” 
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VIII. Appendix 8 – MaTuTU Standard Operating Procedure - Spirometry and 
Reversibility Test 
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1. Introduction 
I. Objective 
The objective of this SOP is to provide general guidance to study personnel on indications and procedures 
to perform a Spirometry and Reversibility Test, specifically it reviews details that influences results, step-
by-step protocol, proper patient preparation and procedures, performing the test.  
II. Background 
Spirometry is a form of pulmonary function test. Patients blow into a tube as strongly as possible, expiring 
until they have no breath left. The Reversibility test consists in the use of a bronchodilator to evaluate 
whether a measured obstruction is fixed or reversible. It is important that all clinical staff use the same 
procedure to this test as specified on this SOP, to ensure continuity, comparability and consistency in re-
sults.  
III. References 
• SOP CISPOC- POP-1001 
• EasyGuide Operator’s Manual 
• SA Guidelines for office spirometry 2012 
• Spirometry testing (Reversibility testing), Sandwell and West Birmingham Hospitals NHS Trust, 
www.swbh.nhs.uk 
• Study protocol; 
• Study Manual of Procedures; 
• Videos: 
https://www.youtube.com/playlist?list=PLEFvavfsN26YG8MJqJ7VCu4_8UmTXoBsc 
https://www.youtube.com/watch?v=6kbgZWS5wH0 
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2. Technical aspects 
 
I. Location 
The Spirometry and Reversibility test should be performed in a specialized examination room. Ensure a 
quiet environment, always maintain room well ventilated and adequate infection control measures (Use 
respirator and gloves). 
 
II. Required equipment 
1. Spirometer 
2. Individual spirette 
3. Noise clip 
4. Inhaler* 
5. Metered Salbutamol*  
6. Absorbent paper  
  * Reversibility test only 
III. Contraindications 
1. Hemoptysis 
2. Pneumothorax 
3. Recent MI (UA) 
4. Aortic Aneurysm 
5. Cerebral Aneurysm 
6. Recent eye surgery 
7. Recent thoracic & abdominal surgery 
8. Contraindication for ß2 agonists use ( hyper sensibility)* 
* Reversibility test only 
 
 
IV. Patient Preparation 
1. Explain the procedure to the participant and answer any questions he/she may have before performing 
the Spirometry (for the first spirometry let the patient watch the video, explain and demonstrate the 
maneuver for the patient).  
2. Emphasize the essential elements of the test: 
• filling lungs completely 
• sealing lips around the spirette so that there are no leaks, taking care not to block its opening with 
teeth or tongue or bite down excessively lasting out as hard and fast as possible 
• continue blowing out until the lungs are completely empty 
3. Obtain verbal consent to perform the Spirometry. 
4. Ask patient to stop taking the following medication for the following time periods before your test 
unless you need to use them because patients symptoms are worsening:  
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5. Ask the patient to refrain from smoking 24 hours before the test.  Avoid eating a large meal for 2 hours 
before the test and avoid vigorous exercise for 30 minutes before the test  
6. Ask the patient to avoid alcohol on the day before the test also ask wear comfortable and loose clothes, 
remove dentures, and relax. 
 
V. Spirometry procedures 
The appointment will take up to 1 ½ hours; this includes the time for the medication to work if neces-
sary (after the first test) and the time to do the 2nd spirometry test.  
Measure patient’s weight and body temperature and record all data needed in the spirometer to generate 
results, check patient file.  
1. Ask patient to seat on a fixed chair. Switch on the EasyOne Worldspirometer. 
• Choose “Perform Test” in the main menu and then NEW. Confirm withNTER. The instru-
ment will now allow you to enter the patient data. 
• Enter the corresponding patient data line by line. Use the keys and confirm with ENTER 
each time. 
• After entering the patient data, you then move on to the "Test selection" menu. Choose the 
FVC Expiratory test and confirm with ENTER. 
• Insert a spirette into the instrument. Ensure that the arrow on the spirette is lined up with 
the arrow on the instrument. 
• Once again briefly prepare the patient for the test. When the patient is ready, press ENTER. 
You will now hear the sensor buzzing. 
• The instrument now prompts you to avoid air flow in the spirette since it is setting the 
baseline. It is advisable to block off the spirette on one end in order to ensure that the 
baseline is set precisely even if the room is draughty. An audible signal will sound when 
the baseline has been set. You will see prompt "Blast out" on the screen. 
• Hand the instrument to the patient. Ask the patient to breathe in deeply, insert the 
spiretteTM correctly into his or her mouth. Now ask the patient to exhale as firmly and as 
quickly as possible, and continue exhaling until all air has been exhaled. 
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• At the end of the maneuver, you will see a message on the display indicating whether the 
maneuver was acceptable. At least three acceptable maneuvers must have been performed 
before you see message "Session complete". 
 
2. After each maneuver recognize a poor effort by observing the patient and/or interpreting the 
Quality Messages displayed by the spirometer. After a poor effort you must explain what went 
wrong. 
3. The patient will be asked to repeat this a few times (at least 3 times, maximum 8 times) trying 
to achieve the best possible quality section (quality A). Develop enthusiastic coaching tech-
niques to use during the maneuver to maximize your chances of getting quality results with a 
minimum number of efforts. 
 
VI. Reversibility test 
If FEV1/FVC < 0.7 is Important to determine if a fixed or reversible air narrowing is present. If FEV1 
increases by more than 12% or 200ml after application of a bronchodilatator (e.g. Salbutamol) there is 
a high likelihood for asthma, instead of or in addition to COPD. 
 
1. The patient should be clinically stable and there should be no contra-indications for the use of 
Salbutamol or other bronchodilating drugs. 
2. Confirm if Measured FEV1/FVC before bronchodilator was below 0.7. 
3. Use metered dose inhaler through a spacer. 
4. After a gentle expiration to Forced Residual Capacity, a dose of 100 μg of salbutamol (or equiva-
lent) is inhaled in one breath to Total Lung Capacity. The breath is then held for 10 s before exhal-
ing. Four separate doses (total dose 400 μg) are delivered at 30 s intervals. 
5. A waiting period of 15 - 20 minutes follows. 
6. Perform 2nd spirometry test (see instruction above). 
 
7. Calculating bronchodilator reversibility: 
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IX. Appendix 9 – MaTuTU Standard Operating Procedure - 6 Minute Walk 
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Appendixes: MaTuTU 6MWT 
 MaTuTU Borg scale 
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1. Introduction 
I. Objective 
The objective of this SOP is to provide  practical guideline for 6 Minute Walk Test (6MWT), specifically 
it reviews details factor that influences results, step-by-step protocol, safety measures, proper patient prep-
aration and procedures and clinical interpretation of results. 
II. Background 
Several modalities are available for the objective of functional exercise capacity. Some provide a very 
complete assessment of all systems involved, whereas others provide lower information and are simpler to 
perform. 6MWT is a practical simple test that requires a 30 m hallway but no advanced equipment or 
advanced training for technician. 
This test measures the distance the patient can quickly walk in a flat, hard surface in a period of 6 minutes, 
it evaluates global integrated response of all systems integrated during the exercise including pulmonary 
and cardiovascular systems, systemic circulation, blood, neuromuscular units and muscle metabolism. 
 
The self-paced 6MWT access the sub maximal level of functional capacity, most patients does not achieve 
maximal exercise capacity during 6MWT instead they choose their own intensity of exercise and are al-
lowed to stop and rest during the test. However most activities of daily living are performed at submaximal 
levels of exertion, the 6MWT may better reflect the functional exercise level for daily physical activities. 
 
III. References 
• ATS statement: Guidelines for the Six Minute Walk Test; 
• Study protocol; 
• Study Manual of Procedures; 
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2. Contraindications 
 
• Unstable angina or Myocardial infarction during previous month; 
• Resting heart rate > 120 bpm; 
• Systolic Blood pressure > 180 mmHg or Diastolic >100 mmHg; 
• Abnormal ECG; 
 
 
3. Safety Issues 
 
• Testing should performed in a location where rapid and appropriate response to an emergency is 
possible; the appropriate position of the crash cart should be determined by the supervising clini-
cian of the facility; 
• Oxygen must be available; a telephone must be in place to enable a call for help; 
• A certified individual should be available if necessary; 
• Physicians a not necessary to be present during all the test; 
• If patient is in on oxygen therapy, oxygen should be given in standard rate or has direct by Physician 
or protocol;  
 
Reasons for immediately stopping 6 MWT include the following:  
Chest pain, Intolerable Dyspnoea, Leg cramps, Staggering, Diaphoresis, Pale or ashen appearance. 
 
Technicians must be trained to recognize any of these situations and respond accordingly. If test is 
stopped due to any of these conditions patients should sit or lie supine. 
The following should be obtained: Blood pressure, Heart rate, Oxygen saturation and physical examina-
tion. Oxygen should be administered as appropriate. 
4. Technical aspects 
 
Location 
The 6 MWT should be performed in a flat, straight, hard surface, seldom travelled corridor. 
The walking course must be 30 m and marked each 3 m, the turnaround point should be marked with a 
cone and starting line marked with brightly tape. If test is done outside take particularly attention to 
weather conditions. 
 
           Required equipment 
1. Countdown timer (or stopwatch) 
2. Mechanical lap counter 
3. Two small cones to mark the turnaround points 
4. A chair that can be easily moved along the walking course 
5. Worksheets on a clipboard 
6. A source of oxygen 
7. Sphygmomanometer  
8. Telephone 
 
           Patient Preparation 
1. Comfortable clothing should be worn. 
2. Appropriate shoes for walking should be worn. 
3. Patients should use their usual walking aids during the test (cane, walker, etc.). 
4. The patient’s usual medical regimen should be continued. 
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5. A light meal is acceptable before early morning or early afternoon tests. 
6. Patients should not have exercised vigorously within 2 hours of beginning the test.  
 
           Measurements 
1. Repeat testing should be performed about the same time of day to minimize intraday variability; 
 
2. “Warm-up” period before the test should not be performed. 
 
3. The patient should sit at rest in a chair, located near the starting position, for at least 10 minutes before 
the test starts. During this time, check for contraindications, measure pulse, respiratory rate and blood 
pressure, and make sure that clothing and shoes are appropriate. Complete the first portion of the work-
sheet (see the APPENDIX). 
 
4. Measure and record baseline heart rate and oxygen saturation (SpO2)). Make sure the readings are 
stable before recording. Note pulse regularity and whether the oximeter signal quality is acceptable. 
 
5. Have the patient stand and rate their baseline dyspnoea and overall fatigue using the Borg scale. 
 
6. Set the lap counter to zero or  tick marks on the worksheet and the timer to 6 minutes. Assemble 
all necessary equipment (lap counter, timer, clipboard, Borg Scale, worksheet) and move to the starting 
point. 
 
7. Instruct the patient as follows: 
 
“The object of this test is to walk as far as possible for 6 minutes. You will walk back and forth in this 
hallway. Six minutes is a long time to walk, so you will be exerting yourself. 
You will probably get out of breath or become exhausted. 
You are permitted to slow down, to stop, and to rest as necessary.  
You may lean against the wall while resting, but resume walking as soon as you are able. You will be 
walking back and forth around the cones. 
You should pivot briskly around the cones and continue back the other way without hesitation. Now I’m 
going to show you. Please watch the way I turn without hesitation.” 
Demonstrate by walking one lap yourself. Walk and pivot around a cone briskly. 
“Are you ready to do that? I am going to use this counter to keep track of the number of laps you com-
plete. I will click it each time you turn around at this starting line. Remember that the object is to walk AS 
FAR AS POSSIBLE for 6 minutes, but don’t run or jog. Start now, or whenever you are ready.” 
 
8. Position the patient at the starting line. Stand near the starting line during the test, do not walk with the 
patient. As long as the patient starts walking start the timer. 
 
9. Do not talk to anyone during the walk. Use an even tone of voice when using the standard phrases of 
encouragement. Watch the patient. Do not get distracted and lose count of the laps. Each time the participant 
returns to the starting line, click the lap counter once (or mark the lap on the worksheet). Let the participant 
see you do it. Exaggerate the click using body language, like using a stopwatch at a race. 
 
After the first minute, tell the patient the following (in even tones):  
 
“You are doing well. You have 5 minutes to go.” 
 
When the timer shows 4 minutes remaining, tell the patient 
the following: “Keep up the good work. You have 4 minutes to go.” 
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When the timer shows 3 minutes remaining, tell the patient the following: “You are doing well. You are 
halfway done.” 
 
When the timer shows 2 minutes remaining, tell the patient the following: “Keep up the good work. You 
have only 2 minutes left.”  
When the timer shows only 1 minute remaining, tell the patients: “You are doing well. You have only 1 
minute to go.”Do not use other words of encouragement (or body language to speed up). 
 
If the patient stops walking during the test and needs a rest, say this: “You can lean against the wall if you 
would like; then continue walking whenever you feel able.” Do not stop the timer. If the patient stops before 
the 6 minutes are up and refuses to continue (or you decide that they should not continue), wheel the chair 
over for the patient to sit on, discontinue the walk, and note on the worksheet the distance, the time stopped, 
and the reason for stopping prematurely. 
 
When the timer is 15 seconds from completion, say this: “In a moment I’m going to tell you to stop. When 
I do, just stop right where you are and I will come to you.” When the timer rings (or buzzes), say this: 
“Stop!” Walk over to the patient. Consider taking the chair if they look exhausted. Mark the spot where 
they stopped by placing a bean bag or a piece of tape on the floor. 
 
10. Post-test: Record the post walk Borg dyspnoea and fatigue levels and ask this: “What, if anything, kept 
you from walking farther?” 
 
11. If using a pulse oximeter, measure SpO2 and pulse rate from the oximeter and then remove the sensor. 
 
12. Record the number of laps from the counter or tick marks on the worksheet. 
 
13. Record the additional distance covered (the number of meters in the final partial lap) using the markers 
on the floor as distance guides. Calculate the total distance walked, rounding to the nearest meter, and 
record it on the worksheet. 
 
14. Congratulate the patient on good effort and offer a drink of water. 
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APPENDIX 
 
1. Modified Borg Dyspnoea and Fatigue Scale 
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